CA2908613A1 - Molecular nets on solid phases - Google Patents
Molecular nets on solid phasesInfo
- Publication number
- CA2908613A1 CA2908613A1 CA2908613A CA2908613A CA2908613A1 CA 2908613 A1 CA2908613 A1 CA 2908613A1 CA 2908613 A CA2908613 A CA 2908613A CA 2908613 A CA2908613 A CA 2908613A CA 2908613 A1 CA2908613 A1 CA 2908613A1
- Authority
- CA
- Canada
- Prior art keywords
- analyte
- molecular
- molecular net
- solid phase
- capture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000007790 solid phase Substances 0.000 title claims abstract description 59
- 239000012491 analyte Substances 0.000 claims abstract description 161
- 239000000523 sample Substances 0.000 claims abstract description 66
- 125000006850 spacer group Chemical group 0.000 claims abstract description 61
- 238000004519 manufacturing process Methods 0.000 claims abstract description 28
- 230000027455 binding Effects 0.000 claims abstract description 27
- 239000011159 matrix material Substances 0.000 claims abstract description 20
- 239000004005 microsphere Substances 0.000 claims abstract description 10
- 239000013307 optical fiber Substances 0.000 claims abstract description 8
- 229910052751 metal Inorganic materials 0.000 claims abstract description 7
- 239000002184 metal Substances 0.000 claims abstract description 7
- 239000002086 nanomaterial Substances 0.000 claims abstract 3
- 239000002077 nanosphere Substances 0.000 claims abstract 3
- 239000010410 layer Substances 0.000 claims description 132
- 238000000034 method Methods 0.000 claims description 61
- 230000008859 change Effects 0.000 claims description 27
- 108090000623 proteins and genes Proteins 0.000 claims description 17
- 230000005291 magnetic effect Effects 0.000 claims description 16
- 102000004169 proteins and genes Human genes 0.000 claims description 16
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 8
- 150000007523 nucleic acids Chemical class 0.000 claims description 8
- 108020004707 nucleic acids Proteins 0.000 claims description 7
- 102000039446 nucleic acids Human genes 0.000 claims description 7
- 229920000642 polymer Polymers 0.000 claims description 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 7
- 108010088751 Albumins Proteins 0.000 claims description 5
- 102000009027 Albumins Human genes 0.000 claims description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 5
- 239000011521 glass Substances 0.000 claims description 5
- 229920001223 polyethylene glycol Polymers 0.000 claims description 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 5
- 102000004190 Enzymes Human genes 0.000 claims description 4
- 108090000790 Enzymes Proteins 0.000 claims description 4
- 238000002835 absorbance Methods 0.000 claims description 4
- 150000001720 carbohydrates Chemical class 0.000 claims description 4
- 239000002041 carbon nanotube Substances 0.000 claims description 4
- 229910021393 carbon nanotube Inorganic materials 0.000 claims description 4
- 150000002632 lipids Chemical class 0.000 claims description 4
- 239000000377 silicon dioxide Substances 0.000 claims description 4
- 108020004711 Nucleic Acid Probes Proteins 0.000 claims description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims description 3
- 238000004925 denaturation Methods 0.000 claims description 3
- 230000036425 denaturation Effects 0.000 claims description 3
- 230000008014 freezing Effects 0.000 claims description 3
- 238000007710 freezing Methods 0.000 claims description 3
- 238000002844 melting Methods 0.000 claims description 3
- 230000008018 melting Effects 0.000 claims description 3
- 239000002853 nucleic acid probe Substances 0.000 claims description 3
- 239000004033 plastic Substances 0.000 claims description 3
- 229920003023 plastic Polymers 0.000 claims description 3
- 239000010409 thin film Substances 0.000 claims description 3
- 238000001962 electrophoresis Methods 0.000 claims 4
- 230000000704 physical effect Effects 0.000 claims 4
- 238000001514 detection method Methods 0.000 abstract description 25
- 238000005259 measurement Methods 0.000 abstract description 21
- 238000000746 purification Methods 0.000 abstract description 11
- 230000007717 exclusion Effects 0.000 abstract description 4
- 238000001914 filtration Methods 0.000 abstract description 3
- 230000003321 amplification Effects 0.000 abstract description 2
- 238000003199 nucleic acid amplification method Methods 0.000 abstract description 2
- 239000007791 liquid phase Substances 0.000 abstract 1
- 239000002245 particle Substances 0.000 description 88
- 239000000427 antigen Substances 0.000 description 38
- 108091007433 antigens Proteins 0.000 description 38
- 102000036639 antigens Human genes 0.000 description 38
- 239000011859 microparticle Substances 0.000 description 26
- 238000003556 assay Methods 0.000 description 18
- 102000004127 Cytokines Human genes 0.000 description 17
- 108090000695 Cytokines Proteins 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 16
- 238000012544 monitoring process Methods 0.000 description 15
- 239000011148 porous material Substances 0.000 description 15
- 238000012360 testing method Methods 0.000 description 15
- 101710120037 Toxin CcdB Proteins 0.000 description 14
- 201000010099 disease Diseases 0.000 description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 14
- 230000001419 dependent effect Effects 0.000 description 12
- 230000004044 response Effects 0.000 description 12
- 238000013459 approach Methods 0.000 description 11
- 210000003719 b-lymphocyte Anatomy 0.000 description 10
- 239000011324 bead Substances 0.000 description 10
- 230000001900 immune effect Effects 0.000 description 10
- 238000005070 sampling Methods 0.000 description 10
- 230000008901 benefit Effects 0.000 description 9
- 208000015181 infectious disease Diseases 0.000 description 8
- 230000003993 interaction Effects 0.000 description 8
- 108020004999 messenger RNA Proteins 0.000 description 8
- 230000003287 optical effect Effects 0.000 description 8
- 244000005700 microbiome Species 0.000 description 7
- 230000004048 modification Effects 0.000 description 7
- 238000012986 modification Methods 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 230000035945 sensitivity Effects 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 230000008685 targeting Effects 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 6
- 230000022131 cell cycle Effects 0.000 description 6
- 238000013461 design Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000003018 immunoassay Methods 0.000 description 6
- 230000009871 nonspecific binding Effects 0.000 description 6
- -1 polyethylene Polymers 0.000 description 6
- 238000002255 vaccination Methods 0.000 description 6
- VLARLSIGSPVYHX-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 6-(2,5-dioxopyrrol-1-yl)hexanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCN1C(=O)C=CC1=O VLARLSIGSPVYHX-UHFFFAOYSA-N 0.000 description 5
- 102100037591 Neuroserpin Human genes 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 230000002759 chromosomal effect Effects 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 230000002458 infectious effect Effects 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- 108010080874 neuroserpin Proteins 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 4
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 4
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 4
- 101000601724 Homo sapiens Paired box protein Pax-5 Proteins 0.000 description 4
- 102000003814 Interleukin-10 Human genes 0.000 description 4
- 108090000174 Interleukin-10 Proteins 0.000 description 4
- 102100037504 Paired box protein Pax-5 Human genes 0.000 description 4
- 102400001018 Proadrenomedullin N-20 terminal peptide Human genes 0.000 description 4
- 101800000795 Proadrenomedullin N-20 terminal peptide Proteins 0.000 description 4
- 239000000556 agonist Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000003792 electrolyte Substances 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 230000004481 post-translational protein modification Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- RPENMORRBUTCPR-UHFFFAOYSA-M sodium;1-hydroxy-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].ON1C(=O)CC(S([O-])(=O)=O)C1=O RPENMORRBUTCPR-UHFFFAOYSA-M 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- QLHLYJHNOCILIT-UHFFFAOYSA-N 4-o-(2,5-dioxopyrrolidin-1-yl) 1-o-[2-[4-(2,5-dioxopyrrolidin-1-yl)oxy-4-oxobutanoyl]oxyethyl] butanedioate Chemical compound O=C1CCC(=O)N1OC(=O)CCC(=O)OCCOC(=O)CCC(=O)ON1C(=O)CCC1=O QLHLYJHNOCILIT-UHFFFAOYSA-N 0.000 description 3
- 208000035473 Communicable disease Diseases 0.000 description 3
- 239000004971 Cross linker Substances 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 108010013639 Peptidoglycan Proteins 0.000 description 3
- 239000004698 Polyethylene Substances 0.000 description 3
- 239000004793 Polystyrene Substances 0.000 description 3
- 230000018199 S phase Effects 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 230000003172 anti-dna Effects 0.000 description 3
- 238000012575 bio-layer interferometry Methods 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 210000002865 immune cell Anatomy 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 208000027866 inflammatory disease Diseases 0.000 description 3
- 108091070501 miRNA Proteins 0.000 description 3
- 239000002679 microRNA Substances 0.000 description 3
- 210000000440 neutrophil Anatomy 0.000 description 3
- 238000007481 next generation sequencing Methods 0.000 description 3
- 229920002223 polystyrene Polymers 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 230000035939 shock Effects 0.000 description 3
- 239000002356 single layer Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 108700020463 BRCA1 Proteins 0.000 description 2
- 102000036365 BRCA1 Human genes 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 230000010190 G1 phase Effects 0.000 description 2
- 101001003584 Homo sapiens Prelamin-A/C Proteins 0.000 description 2
- 241000588748 Klebsiella Species 0.000 description 2
- 108091080995 Mir-9/mir-79 microRNA precursor family Proteins 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 102100026531 Prelamin-A/C Human genes 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 241000589516 Pseudomonas Species 0.000 description 2
- 241000191940 Staphylococcus Species 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000003466 anti-cipated effect Effects 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 239000003596 drug target Substances 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 239000002095 exotoxin Substances 0.000 description 2
- 231100000776 exotoxin Toxicity 0.000 description 2
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- 108091047084 miR-9 stem-loop Proteins 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 102100035248 Alpha-(1,3)-fucosyltransferase 4 Human genes 0.000 description 1
- 101150072950 BRCA1 gene Proteins 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 101000687585 Caenorhabditis elegans REST corepressor spr-1 Proteins 0.000 description 1
- 101710163595 Chaperone protein DnaK Proteins 0.000 description 1
- 101000687583 Drosophila melanogaster REST corepressor Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 101710146739 Enterotoxin Proteins 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 230000010337 G2 phase Effects 0.000 description 1
- 101710178376 Heat shock 70 kDa protein Proteins 0.000 description 1
- 101710152018 Heat shock cognate 70 kDa protein Proteins 0.000 description 1
- 101001022185 Homo sapiens Alpha-(1,3)-fucosyltransferase 4 Proteins 0.000 description 1
- 101000765010 Homo sapiens Beta-galactosidase Proteins 0.000 description 1
- 101001038051 Homo sapiens Phlorizin hydrolase Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 102000006500 Janus Kinase 3 Human genes 0.000 description 1
- 108010019421 Janus Kinase 3 Proteins 0.000 description 1
- 108010059881 Lactase Proteins 0.000 description 1
- 230000027311 M phase Effects 0.000 description 1
- 108010031099 Mannose Receptor Proteins 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 238000002944 PCR assay Methods 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 239000004012 Tofacitinib Substances 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000009830 antibody antigen interaction Effects 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- 238000000429 assembly Methods 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000003990 capacitor Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 102000003675 cytokine receptors Human genes 0.000 description 1
- 108010057085 cytokine receptors Proteins 0.000 description 1
- 238000004163 cytometry Methods 0.000 description 1
- 238000000326 densiometry Methods 0.000 description 1
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000007847 digital PCR Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 238000000295 emission spectrum Methods 0.000 description 1
- 239000000147 enterotoxin Substances 0.000 description 1
- 231100000655 enterotoxin Toxicity 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000002376 fluorescence recovery after photobleaching Methods 0.000 description 1
- 238000007306 functionalization reaction Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 230000008611 intercellular interaction Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 238000010030 laminating Methods 0.000 description 1
- 238000010329 laser etching Methods 0.000 description 1
- 238000007648 laser printing Methods 0.000 description 1
- 238000012125 lateral flow test Methods 0.000 description 1
- 238000001459 lithography Methods 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 108010026228 mRNA guanylyltransferase Proteins 0.000 description 1
- 238000007885 magnetic separation Methods 0.000 description 1
- 230000005389 magnetism Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000002705 metabolomic analysis Methods 0.000 description 1
- 230000001431 metabolomic effect Effects 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000009149 molecular binding Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 238000007837 multiplex assay Methods 0.000 description 1
- 239000002090 nanochannel Substances 0.000 description 1
- 239000002071 nanotube Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000011896 sensitive detection Methods 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000006277 sulfonation reaction Methods 0.000 description 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- UJLAWZDWDVHWOW-YPMHNXCESA-N tofacitinib Chemical compound C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 UJLAWZDWDVHWOW-YPMHNXCESA-N 0.000 description 1
- 229960001350 tofacitinib Drugs 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54353—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals with ligand attached to the carrier via a chemical coupling agent
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
Abstract
Disclosed is a covalently-linked multilayered three-dimensional matrix comprising capture molecules, linkers and spacers (referred to as a Molecular Net) for specific and sensitive analyte capture from a sample. Also disclosed herein is a Molecular Net comprising covalently- linked multilayered three-dimensional matrix comprising more than one type of capture molecule and more than one type of linker and may comprise one or more spacer for specific and sensitive capture of more than one type of analyte from a sample. A Molecular Net may comprise a pseudorandom nature. Use of various capture molecules, linkers and spacers in a Molecular Net may confer unique binding properties to a Molecular Net. Porosity, binding affinity, size exclusion abilities, filtration abilities, concentration abilities and signal amplification abilities of a Molecular Net may be varied and depend on the nature of components used in its fabrication. Uses of a Molecular Net may include analyte capture, analyte enrichment, analyte purification, analyte detection, analyte measurement and analyte delivery. Molecular Nets may be used in liquid phase or on solid phases such as nanomaterials, modified metal surfaces, nanospheres, microspheres, microtiter plates, slides, pipettes, cassettes, cartridges, discs, probes, lateral flow devices, microfiuidics devices, microfiuidics devices, optical fibers and others.
Description
2 PCT/US2014/029823 MOLECULAR NETS ON SOLID PHASES
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the benefit of U.S. provisional application serial no.
61/783,189, filed March 14, 2013, and is a continuation-in-part of U.S. patent application serial nos. 13/511,364, filed May 22, 2012, and 13/938,055, filed July 9, 2013, which are hereby incorporated by reference in their entireties.
BACKGROUND
[0002] Current strategies for solid phase analyte capture, analyte detection and analyte measurement exist using a single layer of capture molecules absorbed or covalently tethered to a surface for direct real-time sensing or are used in conjunction with secondary detection steps in an indirect detection modality are well known in the art. Both direct and indirect methods have demonstrated limitations in sensitivity, specificity, signal-to-noise ratio and/or cost.
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the benefit of U.S. provisional application serial no.
61/783,189, filed March 14, 2013, and is a continuation-in-part of U.S. patent application serial nos. 13/511,364, filed May 22, 2012, and 13/938,055, filed July 9, 2013, which are hereby incorporated by reference in their entireties.
BACKGROUND
[0002] Current strategies for solid phase analyte capture, analyte detection and analyte measurement exist using a single layer of capture molecules absorbed or covalently tethered to a surface for direct real-time sensing or are used in conjunction with secondary detection steps in an indirect detection modality are well known in the art. Both direct and indirect methods have demonstrated limitations in sensitivity, specificity, signal-to-noise ratio and/or cost.
[0003] There is need for analyte capture technology for solid phase surfaces or devices that can selectively capture analytes from a complex sample with little or no sample preparation and to position said selected analytes in a manner to maximize captured analyte measurement and/or detection in a manner that is compatible with most technologies.
SUMMARY
SUMMARY
[0004] Devices for capturing an analyte are described. In one embodiment, a device may comprise a solid phase and a molecular net coupled to at least a portion of a surface of the solid phase. The molecular net may include capture molecules of at least one type coupled to each other by linker molecules of a plurality of types to form a covalently-linked multi-layered three-dimensional matrix. The capture molecules may be configured to bind to the analyte.
[0005] Methods of manufacturing a device for capturing an analyte are also described. In one embodiment, a method may comprise providing a solid phase, and placing a molecular net on at least a portion of a surface of the solid phase. The molecular net may include capture molecules of at least one type coupled to each other by linker molecules of a plurality of types to form a covalently-linked multi-layered three-dimensional matrix. The capture molecules may be configured to bind to the analyte.
[0006] Methods of measuring a quantity of an analyte in a sample are also described. In one embodiment, a method may comprise providing one or more devices each comprising a solid phase and a molecular net covering at least a portion of a surface of the solid phase. The molecular net may include capture molecules of at least one type coupled to each other by linker molecules of a plurality of types to form a covalently-linked multi-layered three-dimensional matrix. The capture molecules configured to bind to the analyte. The method also comprises exposing the devices to the sample and allowing at least a portion of the analyte to bind to the capture molecules of the molecular nets of the devices.
BRIEF DESCRIPTION OF THE DRAWINGS
BRIEF DESCRIPTION OF THE DRAWINGS
[0007] FIG. 1 shows a comparison of traditionally conjugated microparticles and Molecular Net microparticles in IgG purification.
[0008] FIG. 2 shows a traditional capture molecule conjugation to microparticles and the corresponding analyte measurement capability.
[0009] FIG. 3 shows an effectiveness of Molecular Net microparticles in measuring analyte.
[0010] FIG. 4 shows an effectiveness of a Molecular Net with topology in measuring analyte.
[0011] FIG. 5 shows a comparison of traditionally conjugated microparticles and Molecular Net microparticles in a Tau ELISA.
[0012] FIG. 6 shows a comparison of traditionally conjugated microparticles and Molecular Net microparticles in a TSH Luminex sandwich immunoassay.
[0013] FIG. 7 shows an exemplary Molecular Nets on particles.
[0014] FIG. 8 shows an exemplary Molecular Net topological features on particles.
[0015] FIG. 9 shows an exemplary Molecular Nets for analyte delivery.
DESCRIPTION
DESCRIPTION
[0016] It has been shown in U.S. patent serial nos. 61/281,991, 61/337,257, 61/340,287, 61/343,467, 61/410,837, 61/489,646, and 61/489,648, each of which are hereby incorporated by reference, that the construction and use of a covalently-linked pseudorandom multilayered three-dimensional matrix enables the rapid and specific capture of protein, nucleic acid, carbohydrate, lipid, cell or other analytes from an unprocessed sample and that the use of such Molecular Net may be a significant improvement upon conventional analyte binding approaches.
Design and Fabrication of Molecular Nets
Design and Fabrication of Molecular Nets
[0017] Properties of Molecular Nets may be imparted by: the capture molecules selected for use (examples of capture molecules may include antibodies, nucleic acid probes, enzymes, recombinant proteins, peptides and others); the resultant specificity said capture molecules impart; the size and number of selected capture molecules; the placement and spacing of the capture molecules in the molecular Net layer(s); the combination of capture molecules; the order in which the capture molecules may be used; and the ratio of capture molecules to linker molecules and spacer molecules used.
[0018] Properties of Molecular Nets may also be imparted by: the linker molecules selected for use (examples of linker molecules include homobifunctional, heterobifunctional, trifunctional and multifunctional types); the chemical specificity of the linker molecules; the Angstrom length of the linker molecules; the combination of linker molecules;
the order in which the linker molecules may be used; and the ratio of capture molecules to linker molecules and spacer molecules used.
the order in which the linker molecules may be used; and the ratio of capture molecules to linker molecules and spacer molecules used.
[0019] Properties of Molecular Nets may also be imparted by: the spacer molecules selected for use (examples of spacer molecules include PEG, polymer, nucleic acid, albumin, Fc region, peptide, and other); the chemical properties of the spacer molecules;
the size and number of spacer molecules; the order in which the spacer molecules may be used; and the ratio of spacer molecules to linker molecules and capture molecules used.
the size and number of spacer molecules; the order in which the spacer molecules may be used; and the ratio of spacer molecules to linker molecules and capture molecules used.
[0020] Placement and spacing of the capture molecules, linker molecules and spacer molecules may: confer a characteristic topology on the Molecular Net surface;
confer a characteristic density within each layer of a Molecular Net; confer a characteristic porosity of a Molecular Net; remove spatial constraints and thus stearic hindrance; improve binding capacity;
reduce non-specific binding; enable the binding of multiple forms of analyte (for example, simultaneous capture of degraded analyte, whole analyte and complexed analyte), and other.
confer a characteristic density within each layer of a Molecular Net; confer a characteristic porosity of a Molecular Net; remove spatial constraints and thus stearic hindrance; improve binding capacity;
reduce non-specific binding; enable the binding of multiple forms of analyte (for example, simultaneous capture of degraded analyte, whole analyte and complexed analyte), and other.
[0021] The porosity within a Molecular Net may be random, pseudorandom or irregularly interspersed. Porosity of a Molecular Net may be used to filter a sample; may be used to discriminate binding potential molecules in a sample by size-exclusion; may be used to enable macromolecular or cellular binding due to the reduction in stearic hindrance, or other. The pores of a Molecular Net comprise capture molecules, linker molecules and may comprise spacer molecules. Traditional approaches to generate porosity on a solid phase relates to the mechanical modification of the surface of the solid phase and employ methods such as laser etching, laminating, lithography, laser printing or others to generate pores, holes or other structures in the solid surface. This solid surface is then prepared for accepting conjugating capture molecules. Use of a Molecular Net removes the need for mechanical modification of a surface and is thus more cost-effective. Additionally, traditional approaches are still hampered by the problem of high non-specific binding and require capture chemistry to be bound to the mechanically modified solid phase, which is not an improvement. Additionally, flexibility may be imparted into a Molecular Net as compared to the traditional capture format due to size-exclusion properties conferred by the porosity built into each layer of a Molecular Net. In some layers, pore diameter and depth may be similar or may vary depending on the application. In some layers, pore sizes may vary, the variance of which may depend on the application.
[0022] Porosity that may be imparted on a Molecular Net may include but are not limited to picopores, nanopores, micropores, filtration pores, sieving pores, pockets or other. Porosity may be imparted into a Molecular Net by the selection of and method of incorporation of specific capture molecules, linker molecules and spacer molecules into each layer of a Molecular Net.
Porosity may also be imparted into a Molecular Net by the selection of and method of incorporation of specific capture molecules, linker molecules and spacer molecules used in the fabrication of sequential layers.
Porosity may also be imparted into a Molecular Net by the selection of and method of incorporation of specific capture molecules, linker molecules and spacer molecules used in the fabrication of sequential layers.
[0023] Molecular Net porosity may range from about 6 Angstroms in diameter to more than about 1 um in diameter based on the identity of capture molecules, linker and spacers used in a layer. In some cases, the porosity of a Molecular Net may comprise a range of pore diameters. Exemplary diameter ranges may be from about 5 nm to about 50 nm, from about 10 nm to about 100 nm, from about 50 nm to about 200 nm, from about 250 nm to about 500 nm, from about 500 nm to about 1 um, and from about 800 nm to about 1.5 um.
[0024] In some cases, capture molecules may be used to generate pores in a Molecular Net. In these instances, capture molecules may be pre-linked to one another prior to being incorporated into a Molecular Net layer. In some cases, linkers may be selected based on Angstrom length of the spacer arms. In some examples, extenders may be used to connect a first linker to a second linker to generate a long multi-functional linker. In some cases, spacers may be used to generate pores in a Molecular Net. Spacers may also be pre-linked to one another prior to being incorporated into a Molecular Net layer. In other examples, inert physical plugs may be used to build a pore, whereby each physical plug may be placed on a previously built layer while a new layer is being constructed. After curing, the physical plugs may be removed, thus leaving a pore of a specific diameter.
[0025] The flexible nature of the Molecular Net enables the use of multiple types of capture molecules. In some examples, a Molecular Net comprises a single type of capture molecule. In other examples, a Molecular Net comprises multiple types of capture molecules. In some examples, the use of more than one monoclonal antibody during the fabrication of a Molecular Net enables said Molecular Net to bind more than one epitope of an analyte. Use of more than one type of epitope-specific capture molecule enables improved analyte capture by a Molecular Net and relates to its performance. In some examples, the use of more than one nucleic acid sequence may be used during the fabrication process to generate a Molecular Net capable of binding to more than one epitope of an analyte. Examples of benefit depend on the use of the Molecular Net and may comprise improved performance in terms of minimum levels of detection, sensitivity, positive predictive value, negative predictive value, ability to work with degraded samples, ability to work with a diverse population, and others when used in a test; may comprise improved performance in binding capacity, purity, binding kinetics, target analyte depletion, and others when used as a purification tool; or other.
[0026] In some examples, the use of capture molecules directed against mutually-confirmatory analytes may be used in a Molecular Net and relates to its performance. Use of mutually-confirmatory capture molecules in a Molecular Net may be used in a confirmatory manner, whereby the capture of more than one analyte may provide a more statistically significant positive result; may provide a more robust test result; may provide additional information regarding a sample; and other. Use of mutually-confirmatory capture molecules in a Molecular Net may also be used to qualify a sample or may be used as a control in a test or may be used to measure more than one related molecular variable linked to a disease state or may be used to measure more than one related molecular variable linked to the treatment of a disease.
[0027] Examples of mutually-confirmatory analytes a Molecular Net may be fabricated to simultaneously capture from a sample may include: genetic sequence and corresponding protein product (for examples, cancer-related SNPs in BRCA1 and BRCA1 protein); the mRNA
and corresponding protein product (for example, human lactase mRNA and Lactase protein); the genetic sequence and the corresponding mRNA product (for example, disease-related SNPs in LMNA and pre-spliced or spliced Lamin A/C mRNA); miRNA and related mRNA or protein products (miR 9 and REST or CoREST mRNA, or miR 9 and REST protein); small molecule drugs and drug targets (tofacitinib and Janus kinase 3); epitope-specific biologics and the respective targets (for example, anti-TNF antibodies and circulating TNF
cytokine); epitope-specific antibodies, epitope-specific T cells and/or epitope-specific B cells or the like (for example, anti-DNA autoantibodies, anti-DNA CD4 ' T cells and/or anti-DNA B
cells); or others.
Examples of benefit depend on use and may relate to improved performance in test sensitivity, positive predictive value, negative predictive value, specificity, diagnosis of a disease, ability to work with samples experiencing genetic drift, ability to measure response to a therapeutic, ability to measure effectiveness of a therapeutic, or other.
and corresponding protein product (for example, human lactase mRNA and Lactase protein); the genetic sequence and the corresponding mRNA product (for example, disease-related SNPs in LMNA and pre-spliced or spliced Lamin A/C mRNA); miRNA and related mRNA or protein products (miR 9 and REST or CoREST mRNA, or miR 9 and REST protein); small molecule drugs and drug targets (tofacitinib and Janus kinase 3); epitope-specific biologics and the respective targets (for example, anti-TNF antibodies and circulating TNF
cytokine); epitope-specific antibodies, epitope-specific T cells and/or epitope-specific B cells or the like (for example, anti-DNA autoantibodies, anti-DNA CD4 ' T cells and/or anti-DNA B
cells); or others.
Examples of benefit depend on use and may relate to improved performance in test sensitivity, positive predictive value, negative predictive value, specificity, diagnosis of a disease, ability to work with samples experiencing genetic drift, ability to measure response to a therapeutic, ability to measure effectiveness of a therapeutic, or other.
[0028] In one example, a Molecular Net may be fabricated in a manner to capture and position bound analytes in a manner that enhances the intensity of a detectable signal or may enhance detection of bound analytes, such as when used in a test with optical detection.
Placement of captured analytes in a layered manner by pre-positioned layered capture molecules may enable the rapid detection of analyte by signal intensification. Examples of signal intensification by a Molecular Net may relate to fluorescence, fluorescence resonance energy transfer, absorbance, luminescence, light scatter, surface plasmon resonance, optical heterodyne detection, or other.
Placement of captured analytes in a layered manner by pre-positioned layered capture molecules may enable the rapid detection of analyte by signal intensification. Examples of signal intensification by a Molecular Net may relate to fluorescence, fluorescence resonance energy transfer, absorbance, luminescence, light scatter, surface plasmon resonance, optical heterodyne detection, or other.
[0029] Said Molecular Net may be designed and fabricated to replace the need for costly and time-intensive methods for ultra-sensitive detection such as PCR, branched DNA, or multi-step detection methods required for signal amplification. Said Molecular Net may also be designed and fabricated to replace the need for costly and complicated analytical devices.
[0030] Generally, the number of capture molecules incorporated into a 3-dimensional Molecular Net matrix is less than or equivalent to the number of capture molecules conjugated in a 2-dimensional manner to a surface using conventional approaches. Two-dimensional capture molecule-surface conjugates may rely on the use of a single linker type or may rely on the sequential use of 2 linkers to conjugate capture molecules to a solid surface.
During the fabrication of a layer of a Molecular Net, multiple linker types are used simultaneously to link capture molecule to capture molecule of a new layer and the linked capture molecules of a new layer to a spacer or capture molecule of a previous layer. Molecular Nets may be fabricated in solution prior to placement on a solid surface. Pre-fabricated Molecular Nets may be absorbed or covalently linked to a solid surface. Molecular Nets may also be fabricated directly onto a solid surface, layer by layer. Said Molecular Nets may be placed on a solid surface using non-covalent (electrostatic, van der Waals, or other) or covalent methods. In some instances, polystyrene, polyurethane, polyethylene or treated surfaces such as poly-L-lysine coated surfaces, modified surfaces comprising -COOH, NHS, amine or other may be purchased from commercial sources (examples of vendors may include Thermo, Millipore, Luminex and other) and used as solid phase surfaces for Molecular Net placement. In other instances, solid phase surfaces may be pre-treated by chemicals such as acid to activate the surface moieties and thus to generate attachment points between the solid phase surface and reactive moieties of a Molecular Net. In some examples, a solid phase may be pre-treated with linker to covalently link a solid phase surface to a Molecular Net.
During the fabrication of a layer of a Molecular Net, multiple linker types are used simultaneously to link capture molecule to capture molecule of a new layer and the linked capture molecules of a new layer to a spacer or capture molecule of a previous layer. Molecular Nets may be fabricated in solution prior to placement on a solid surface. Pre-fabricated Molecular Nets may be absorbed or covalently linked to a solid surface. Molecular Nets may also be fabricated directly onto a solid surface, layer by layer. Said Molecular Nets may be placed on a solid surface using non-covalent (electrostatic, van der Waals, or other) or covalent methods. In some instances, polystyrene, polyurethane, polyethylene or treated surfaces such as poly-L-lysine coated surfaces, modified surfaces comprising -COOH, NHS, amine or other may be purchased from commercial sources (examples of vendors may include Thermo, Millipore, Luminex and other) and used as solid phase surfaces for Molecular Net placement. In other instances, solid phase surfaces may be pre-treated by chemicals such as acid to activate the surface moieties and thus to generate attachment points between the solid phase surface and reactive moieties of a Molecular Net. In some examples, a solid phase may be pre-treated with linker to covalently link a solid phase surface to a Molecular Net.
[0031] Design and fabrication of a Molecular Net for use on a solid phase surface may result in a covalently-linked multilayered three-dimensional matrix of capture molecules secured by covalent connectors within each layer. Design and fabrication may occur in a sequential manner where a first layer is fabricated and subsequent layers are fabricated in a sequential manner whereby each layer may be interconnected in a covalent manner to enhance structural integrity, topology, porosity and/or stability. Selection of individual capture molecules, linkers and spacers may be made to contribute to one or more property of a Molecular Net. Properties may comprise analyte specificity, thermal stability, layer thickness, pore diameter, absorbance spectra, emission spectra, solid phase compatibility or other.
[0032] The use of capture molecules and linker molecules and spacers of known lengths and widths may be used to generate various topology on the surface of the Molecular Net.
Topological features that may be imparted on a Molecular Net may include but are not limited to dimples, pocks, stipples, pores, mounds, branches, filaments, fibers, fissures, raised segments or other and may be arranged in a Molecular Net in a random, pseudorandom or irregular manner.
Topological features that may be imparted on a Molecular Net may include but are not limited to dimples, pocks, stipples, pores, mounds, branches, filaments, fibers, fissures, raised segments or other and may be arranged in a Molecular Net in a random, pseudorandom or irregular manner.
[0033] Topological features of a Molecular Net may be generated through the use of capture molecules and linkers; capture molecules, linkers and spacers; or linkers and spacers. In some cases, capture molecules may be used to generate topological features of a Molecular Net.
In these instances, capture molecules may be pre-linked to one another prior to being incorporated covalently into a Molecular Net layer. In some cases, linkers may be selected based on Angstrom length of the spacer arms. In some examples, spacers may be used to connect a first linker to a second linker to generate a long multi-functional linker. In some cases, spacers may be used to generate topological in a Molecular Net. Spacers may also be pre-linked to one another or to capture molecules prior to being incorporated into a Molecular Net layer.
In these instances, capture molecules may be pre-linked to one another prior to being incorporated covalently into a Molecular Net layer. In some cases, linkers may be selected based on Angstrom length of the spacer arms. In some examples, spacers may be used to connect a first linker to a second linker to generate a long multi-functional linker. In some cases, spacers may be used to generate topological in a Molecular Net. Spacers may also be pre-linked to one another or to capture molecules prior to being incorporated into a Molecular Net layer.
[0034] Molecular nets may be designed and fabricated to impart characteristics such as affinity, size exclusion, filtration, fluorescence, and other into each layer of a Molecular Net.
Specific capture molecules, linker molecules and spacer molecules may be selected based on size, length, diameter, thickness, optical properties, chemical properties or other for imparting characteristics into a Molecular Net during the fabrication process.
Specific capture molecules, linker molecules and spacer molecules may be selected based on size, length, diameter, thickness, optical properties, chemical properties or other for imparting characteristics into a Molecular Net during the fabrication process.
[0035] Molecular Nets may be fabricated in a manner whereby one or more capture molecules may serve a structural role, may serve both a structural role and a role in analyte capture within the covalently-linked multilayered three-dimensional matrix.
Some examples of capture molecules that may be used for structural and/or analyte capture roles in a Molecular Net.
Some examples of capture molecules that may be used for structural and/or analyte capture roles in a Molecular Net.
[0036] The distance between capture molecules in each layer of a Molecular Net may be determined, in part, by the diameter, width and/or length of capture molecules, linkers and spacers used in the fabrication process for each layer, whereby the molar relationship between each linker-capture-spacer molecule may be similar or may be different and the selection of said molecules may be dependent on size and/or shape of the analyte to be captured, the method used to measure captured analyte and/or desired use.
[0037] Molecular Nets may be designed and fabricated in a manner whereby each capture molecule, linker and spacer component may have equivalent or non-equivalent molar ratios in a layer of said Molecular Net. Variance of molar ratios between said components may be used from time to time to generate porosities or other topological features within each layer.
Said porosities and topological features may have a range of diameters and may have a range of associated depths. Variance of molar ratios between Molecular Net components may occur in a single layer of Molecular Net or may occur in more than one layer of a Molecular Net and is dependent on the intended use of a Molecular Net.
TABLE 1. Examples of Molecular Net structural components with analyte capture ability.
Examples of Molecular Net Approximate Approximate Structural/Capture Components Diameter (nm) Length (nm) IgG, IgE ¨9 16 IgM 37 37 IgA ¨9 ¨32 Streptavidin & recombinant variants ¨105 (tetrameric) N/A
Protein A & recombinant variants ¨3.2-5.3 N/A
Protein G & recombinant variants ¨3-5.4 N/A
MHC I 3.05 N/A
MHC II 2.99 N/A
TCR 3.34 N/A
CD28 2.75 N/A
TLR 4 2.62 N/A
B7x 4.52 N/A
Taq polymerase ¨6.49 N/A
poly(Arg9) peptide 1.43 N/A
HSP70 3.46 N/A
Said porosities and topological features may have a range of diameters and may have a range of associated depths. Variance of molar ratios between Molecular Net components may occur in a single layer of Molecular Net or may occur in more than one layer of a Molecular Net and is dependent on the intended use of a Molecular Net.
TABLE 1. Examples of Molecular Net structural components with analyte capture ability.
Examples of Molecular Net Approximate Approximate Structural/Capture Components Diameter (nm) Length (nm) IgG, IgE ¨9 16 IgM 37 37 IgA ¨9 ¨32 Streptavidin & recombinant variants ¨105 (tetrameric) N/A
Protein A & recombinant variants ¨3.2-5.3 N/A
Protein G & recombinant variants ¨3-5.4 N/A
MHC I 3.05 N/A
MHC II 2.99 N/A
TCR 3.34 N/A
CD28 2.75 N/A
TLR 4 2.62 N/A
B7x 4.52 N/A
Taq polymerase ¨6.49 N/A
poly(Arg9) peptide 1.43 N/A
HSP70 3.46 N/A
[0038] Some examples of analyte dimensions that may be considered during the design and fabrication process are provided in Table 2. Design and fabrication of Molecular Net surface chemistry, pore diameter, topology, layering or other may be based on analyte shape; analyte structure, analyte isoforms, analyte charge, analyte complex formation with other molecules, and other forms. Furthermore, Molecular Nets may be designed and fabricated to bind and capture said analyte or may be designed and fabricated to exclude said analyte.
Examples of analytes and analyte sizes can be found in Table 2.
TABLE 2. Examples of analytes and their dimensions.
Exemplary Analyte Approximate Diameter Approximate Length (um) (um) E. coli 0.5 1-2 Klebsiella spp. 0.3-1 0.6-6 Pseudomonas spp. 0.6 3 Staphylococcus aureus 1 1 Staphylococcus aureus (cluster) >10 >10 Enterotoxin K ¨4.29 N/A
Peptidoglycan, gram negative ¨2-3, species dependent Highly species dependent bacteria Outer membrane, gram negative ¨7, species dependent Species dependent bacteria IgG, IgE 0.009 0.016 IgA 0.009 0.032 IgM 0.037 0.037 B cell ¨ GO phase of cell cycle 4.5-5.5 N/A
B cell ¨ early G1 phase of cell 5.5-7 N/A
cycle B cell ¨ late G1 and S phase of 7-10 N/A
cell cycle B cell ¨ late S, G2 and M phases 10-12 N/A
of cell cycle Monocyte ¨9-18 N/A
Macrophage 21, activation level N/A
dependent Neutrophil 7.17-9.3, activation level N/A
dependent IL6 monomer ¨4.11 N/A
IL6 multimer (variable) ¨6.16 N/A
IL 10 monomer ¨3.88 N/A
IL 10 multimer (variable) ¨7.7 N/A
microRNA-146 a ¨3-6 ¨7-9
Examples of analytes and analyte sizes can be found in Table 2.
TABLE 2. Examples of analytes and their dimensions.
Exemplary Analyte Approximate Diameter Approximate Length (um) (um) E. coli 0.5 1-2 Klebsiella spp. 0.3-1 0.6-6 Pseudomonas spp. 0.6 3 Staphylococcus aureus 1 1 Staphylococcus aureus (cluster) >10 >10 Enterotoxin K ¨4.29 N/A
Peptidoglycan, gram negative ¨2-3, species dependent Highly species dependent bacteria Outer membrane, gram negative ¨7, species dependent Species dependent bacteria IgG, IgE 0.009 0.016 IgA 0.009 0.032 IgM 0.037 0.037 B cell ¨ GO phase of cell cycle 4.5-5.5 N/A
B cell ¨ early G1 phase of cell 5.5-7 N/A
cycle B cell ¨ late G1 and S phase of 7-10 N/A
cell cycle B cell ¨ late S, G2 and M phases 10-12 N/A
of cell cycle Monocyte ¨9-18 N/A
Macrophage 21, activation level N/A
dependent Neutrophil 7.17-9.3, activation level N/A
dependent IL6 monomer ¨4.11 N/A
IL6 multimer (variable) ¨6.16 N/A
IL 10 monomer ¨3.88 N/A
IL 10 multimer (variable) ¨7.7 N/A
microRNA-146 a ¨3-6 ¨7-9
[0039] Molecular Nets comprising structural components and capture components may be arranged in the covalently linked 3-dimensional (3D) multilayered matrix and may relate to the capture of one or more analyte relating to one or more of the following characteristics:
surface chemistry; analyte shape; analyte structure; analyte isoforms; analyte charge; post-translational modification; chemical modification; activity; or other.
surface chemistry; analyte shape; analyte structure; analyte isoforms; analyte charge; post-translational modification; chemical modification; activity; or other.
[0040] Molecular Nets may comprise structural components that also act in a manner relating to the capture of analytes and may be arranged in the interconnected 3D multilayered matrix of a Molecular Net by covalent linkers. A Molecular Net may also comprise spacers to interconnect said structure/capture molecules in a manner to maximize structural reinforcement, stability and/or specific analyte capture capability. Molecular Net examples comprising capture components/structural components, linkers and spacers are presented in Table 3.
[0041] Fabrication of the molecular Net is unique in that capture molecules are secured in a 3D matrix by covalent linker molecules. In numerous studies, Molecular Nets have been demonstrated to have improved thermal stability and extend shelf-life beyond traditional capture technologies.
TABLE 3. Examples of Molecular Nets and their Use.
Analyte to Capture Molecules to Methods of Anticipated Use Capture Use for Affinity Generating Size Capture Exclusion E. coli Antibodies against Covalently linked Diagnostics:
Food surface antigens (e.g., antibodies ¨ IgG, safety, infectious LPS, 0-antigen, pili, IgM, covalent disease, water safety;
other); PNA probes linkers, spacers Molecular tools:
against chromosomal polymicrobial and/or plasmid DNA sampling, microbiome sampling, molecular biology Klebsiella spp. Antibodies against Covalently linked Diagnostics:
Food surface antigens (e.g., antibodies ¨ IgG, safety, infectious LPS, other); PNA IgM, covalent disease, water safety;
probes against linkers, spacers Molecular tools:
chromosomal and/or polymicrobial plasmid DNA sampling, microbiome sampling, molecular biology Pseudomonas spp. Antibodies against Covalently linked Diagnostics:
Food surface antigens (e.g., antibodies ¨ IgG, safety, infectious LPS, V antigen, other), IgM, covalent disease, water safety;
excreted materials linkers, spacers Molecular tools:
(e.g., heat shock polymicrobial proteins, alginate, sampling, microbiome other); PNA probes sampling, molecular against chromosomal biology and/or plasmid DNA
Staphylococcus Antibodies against Covalently linked Diagnostics: Food aureus surface antigens (e.g., antibodies ¨ IgG, safety, infectious protein A, IgM, covalent disease, water safety;
peptidoglycan, other), linkers, spacers Molecular tools:
excreted materials polymicrobial (e.g., heat shock sampling, microbiome proteins, exotoxins, sampling, molecular other); PNA probes biology against chromosomal and/or plasmid DNA
Staphylococcus Antibodies against Covalently linked Diagnostics: Food aureus (cluster) surface antigens (e.g., antibodies ¨ IgG, safety, infectious protein A, IgM, covalent disease, water safety;
peptidoglycan, other), linkers, longer Molecular tools:
excreted materials spacers polymicrobial (e.g., heat shock sampling, microbiome proteins, exotoxins, sampling, molecular other); PNA probes biology against chromosomal and/or plasmid DNA
IgG, IgE Antibodies against Fc Covalently linked Diagnostics:
Immune IgG or IgE; Antibodies antibodies, response profiling, against Fab; antigens antigens, covalent vaccination, antibody linkers, spacers titering; Molecular tools: immunologic studies, pre-clinical studies IgA Antibodies against Fe Covalently linked Diagnostics:
Immune IgA; Antibodies antibodies, response profiling, against Fab IgA; antigens, covalent vaccination, antibody antigens linkers, spacers titering; Molecular tools: immunologic studies, pre-clinical studies IgM Antibodies against Covalently linked Diagnostics:
Immune IgM; Antibodies antibodies, response profiling, against 5 IgM; antigens, covalent vaccination, antibody antigens linkers, spacers titering; Molecular tools: immunologic studies, pre-clinical studies B cell ¨ GO phase Antibodies against Covalently linked Diagnostics:
Immune of cell cycle PAX5, CD19, CD20, antibodies ¨ IgG, response profiling, CD79a, others; IgM, covalent disease monitoring;
antigens; TCR:antigen; linkers, spacers, Molecular tools:
MHC I:antigen; MCH MHC:antigen immunologic studies, II:antigen; cytokines complexes, pre-clinical studies (e.g., IL10, IL6, TGFb, cytokines other) B cell ¨ early G1 Antibodies against Covalently linked Diagnostics:
Immune phase of cell cycle PAX5, CD19, CD20, antibodies ¨ IgG, response profiling, CD79a, others; IgM, covalent disease monitoring;
antigens; TCR:antigen; linkers, spacers, Molecular tools:
MHC I:antigen; MCH MHC:antigen immunologic studies, II:antigen; cytokines complexes, pre-clinical studies (e.g., IL10, IL6, TGFb, cytokines other) B cell ¨ late G1 and Antibodies against Covalently linked Diagnostics:
Immune S phase of cell PAX5, CD19, CD20, antibodies ¨ IgG, response profiling, cycle CD79a, others; IgM, covalent disease monitoring;
antigens; TCR:antigen; linkers, spacers, Molecular tools:
MHC I:antigen; MCH MHC:antigen immunologic studies, II:antigen; cytokines complexes, pre-clinical studies (e.g., IL10, IL6, TGFb, cytokines other) B cell ¨ late S, G2 Antibodies against Covalently linked Diagnostics: Immune and M phases of PAX5, CD19, CD20, antibodies ¨ IgG, response profiling, cell cycle CD79a, others; IgM, covalent disease monitoring;
antigens; TCR:antigen; linkers, spacers, Molecular tools:
MHC I:antigen; MCH MHC:antigen immunologic studies, II:antigen; cytokines complexes, pre-clinical studies (e.g., IL10, IL6, TGFb, cytokines other) Macrophage Complement, Covalently linked Diagnostics:
Immune antibodies against antibodies ¨ IgG, response profiling, mannose receptor Ab, IgM, covalent infectious disease anti-Ly6C, or other; linkers, spacers, monitoring;
antibodies against Ml, MHC:antigen vaccination M2a, M2b, M2c complexes, monitoring; chronic markers; TLR agonists; cytokines, TLR inflammatory disease cytokines; DAMPs; agonists, DAMPs, monitoring;
Molecular PAMPs; alarmins PAMPs, alarmins tools: immunologic studies, pre-clinical studies Neutrophil Complement, Covalently linked Diagnostics:
Immune antibodies against antibodies ¨ IgG, response profiling, CD15, Ly6G or other; IgM, covalent infectious disease antibodies against linkers, spacers, monitoring;
neutrophil markers; MHC:antigen vaccination TLR agonists; complexes, monitoring; chronic cytokines; DAMPs; cytokines, TLR inflammatory disease PAMPs; alarmins agonists, DAMPs, monitoring;
Molecular PAMPs, alarmins tools: immunologic studies, pre-clinical studies Cytokines Antibodies against one Covalently linked Diagnostics:
Immune or more epitope of antibodies ¨ IgG, response profiling, cytokine; cytokine IgM, covalent infectious disease binding domain of linkers, spacers, monitoring;
cytokine receptor; PNA vaccination probes against cytokine monitoring; chronic gene and/or cytokine inflammatory disease mRNA; or other monitoring; Molecular tools: immunologic studies, pre-clinical studies
TABLE 3. Examples of Molecular Nets and their Use.
Analyte to Capture Molecules to Methods of Anticipated Use Capture Use for Affinity Generating Size Capture Exclusion E. coli Antibodies against Covalently linked Diagnostics:
Food surface antigens (e.g., antibodies ¨ IgG, safety, infectious LPS, 0-antigen, pili, IgM, covalent disease, water safety;
other); PNA probes linkers, spacers Molecular tools:
against chromosomal polymicrobial and/or plasmid DNA sampling, microbiome sampling, molecular biology Klebsiella spp. Antibodies against Covalently linked Diagnostics:
Food surface antigens (e.g., antibodies ¨ IgG, safety, infectious LPS, other); PNA IgM, covalent disease, water safety;
probes against linkers, spacers Molecular tools:
chromosomal and/or polymicrobial plasmid DNA sampling, microbiome sampling, molecular biology Pseudomonas spp. Antibodies against Covalently linked Diagnostics:
Food surface antigens (e.g., antibodies ¨ IgG, safety, infectious LPS, V antigen, other), IgM, covalent disease, water safety;
excreted materials linkers, spacers Molecular tools:
(e.g., heat shock polymicrobial proteins, alginate, sampling, microbiome other); PNA probes sampling, molecular against chromosomal biology and/or plasmid DNA
Staphylococcus Antibodies against Covalently linked Diagnostics: Food aureus surface antigens (e.g., antibodies ¨ IgG, safety, infectious protein A, IgM, covalent disease, water safety;
peptidoglycan, other), linkers, spacers Molecular tools:
excreted materials polymicrobial (e.g., heat shock sampling, microbiome proteins, exotoxins, sampling, molecular other); PNA probes biology against chromosomal and/or plasmid DNA
Staphylococcus Antibodies against Covalently linked Diagnostics: Food aureus (cluster) surface antigens (e.g., antibodies ¨ IgG, safety, infectious protein A, IgM, covalent disease, water safety;
peptidoglycan, other), linkers, longer Molecular tools:
excreted materials spacers polymicrobial (e.g., heat shock sampling, microbiome proteins, exotoxins, sampling, molecular other); PNA probes biology against chromosomal and/or plasmid DNA
IgG, IgE Antibodies against Fc Covalently linked Diagnostics:
Immune IgG or IgE; Antibodies antibodies, response profiling, against Fab; antigens antigens, covalent vaccination, antibody linkers, spacers titering; Molecular tools: immunologic studies, pre-clinical studies IgA Antibodies against Fe Covalently linked Diagnostics:
Immune IgA; Antibodies antibodies, response profiling, against Fab IgA; antigens, covalent vaccination, antibody antigens linkers, spacers titering; Molecular tools: immunologic studies, pre-clinical studies IgM Antibodies against Covalently linked Diagnostics:
Immune IgM; Antibodies antibodies, response profiling, against 5 IgM; antigens, covalent vaccination, antibody antigens linkers, spacers titering; Molecular tools: immunologic studies, pre-clinical studies B cell ¨ GO phase Antibodies against Covalently linked Diagnostics:
Immune of cell cycle PAX5, CD19, CD20, antibodies ¨ IgG, response profiling, CD79a, others; IgM, covalent disease monitoring;
antigens; TCR:antigen; linkers, spacers, Molecular tools:
MHC I:antigen; MCH MHC:antigen immunologic studies, II:antigen; cytokines complexes, pre-clinical studies (e.g., IL10, IL6, TGFb, cytokines other) B cell ¨ early G1 Antibodies against Covalently linked Diagnostics:
Immune phase of cell cycle PAX5, CD19, CD20, antibodies ¨ IgG, response profiling, CD79a, others; IgM, covalent disease monitoring;
antigens; TCR:antigen; linkers, spacers, Molecular tools:
MHC I:antigen; MCH MHC:antigen immunologic studies, II:antigen; cytokines complexes, pre-clinical studies (e.g., IL10, IL6, TGFb, cytokines other) B cell ¨ late G1 and Antibodies against Covalently linked Diagnostics:
Immune S phase of cell PAX5, CD19, CD20, antibodies ¨ IgG, response profiling, cycle CD79a, others; IgM, covalent disease monitoring;
antigens; TCR:antigen; linkers, spacers, Molecular tools:
MHC I:antigen; MCH MHC:antigen immunologic studies, II:antigen; cytokines complexes, pre-clinical studies (e.g., IL10, IL6, TGFb, cytokines other) B cell ¨ late S, G2 Antibodies against Covalently linked Diagnostics: Immune and M phases of PAX5, CD19, CD20, antibodies ¨ IgG, response profiling, cell cycle CD79a, others; IgM, covalent disease monitoring;
antigens; TCR:antigen; linkers, spacers, Molecular tools:
MHC I:antigen; MCH MHC:antigen immunologic studies, II:antigen; cytokines complexes, pre-clinical studies (e.g., IL10, IL6, TGFb, cytokines other) Macrophage Complement, Covalently linked Diagnostics:
Immune antibodies against antibodies ¨ IgG, response profiling, mannose receptor Ab, IgM, covalent infectious disease anti-Ly6C, or other; linkers, spacers, monitoring;
antibodies against Ml, MHC:antigen vaccination M2a, M2b, M2c complexes, monitoring; chronic markers; TLR agonists; cytokines, TLR inflammatory disease cytokines; DAMPs; agonists, DAMPs, monitoring;
Molecular PAMPs; alarmins PAMPs, alarmins tools: immunologic studies, pre-clinical studies Neutrophil Complement, Covalently linked Diagnostics:
Immune antibodies against antibodies ¨ IgG, response profiling, CD15, Ly6G or other; IgM, covalent infectious disease antibodies against linkers, spacers, monitoring;
neutrophil markers; MHC:antigen vaccination TLR agonists; complexes, monitoring; chronic cytokines; DAMPs; cytokines, TLR inflammatory disease PAMPs; alarmins agonists, DAMPs, monitoring;
Molecular PAMPs, alarmins tools: immunologic studies, pre-clinical studies Cytokines Antibodies against one Covalently linked Diagnostics:
Immune or more epitope of antibodies ¨ IgG, response profiling, cytokine; cytokine IgM, covalent infectious disease binding domain of linkers, spacers, monitoring;
cytokine receptor; PNA vaccination probes against cytokine monitoring; chronic gene and/or cytokine inflammatory disease mRNA; or other monitoring; Molecular tools: immunologic studies, pre-clinical studies
[0042] In some examples, the solid phase may be particles ranging from about 2 nm in diameter to about 200 mm in diameter and Molecular Nets may be attached to the surface of said particle. Particles may comprise polystyrene, polyethylene, silica, composite, nylon, PVDF, nitrocellulose, cellulosic, carbon, or other may be magnetic, paramagnetic, fluorescent, barcoded or other.
[0043] Molecular Nets may be absorbed or covalently linked to the surface of a particle in manner to generate pseudorandom or ordered porosities in a single layer of said Molecular Net or throughout. In its most basic form, a particle may be initially coated with a layer of Molecular Net, which may be connected to a second layer, which may be connected to a third layer.
Molecular Net layers may comprise the same capture molecules at the same or at different concentrations in each layer. Molecular Net particles may also comprise different capture molecules in each layer and may be fabricated in a manner to incorporate the same or different concentrations of capture molecules compared to previous layers.
Molecular Net layers may comprise the same capture molecules at the same or at different concentrations in each layer. Molecular Net particles may also comprise different capture molecules in each layer and may be fabricated in a manner to incorporate the same or different concentrations of capture molecules compared to previous layers.
[0044] In some examples, Molecular Nets may be attached to a particle surface in a manner to generate an asymmetric particle having a pre-determined polarity.
Such a particle may be designed and fabricated with an initial layer comprising structural molecules with a large diameter, width and/or length and may be linked to a particle in an asymmetric manner to generate a polarity. A second layer may be linked to a first layer and a third layer may be connected to a second layer and so on. The number of layers in a Molecular Net particle may vary depending on use.
Such a particle may be designed and fabricated with an initial layer comprising structural molecules with a large diameter, width and/or length and may be linked to a particle in an asymmetric manner to generate a polarity. A second layer may be linked to a first layer and a third layer may be connected to a second layer and so on. The number of layers in a Molecular Net particle may vary depending on use.
[0045] In some examples, Molecular Nets may be attached to a segment of a particle to generate an asymmetric particle having a pre-determined polarity. Such a particle is constructed whereby the initial layer is coated onto a segment of a particle and whereby a second layer is connected to the initial layer onto the same segment of said particle, and whereby a third layer is connected to the second layer onto the same segment of said particle, and whereby a fourth layer is connected to the third layer onto the same segment of said particle.
[0046] In some examples, Molecular Nets may be passively absorbed to a nonfunctionalized particle surface. In other examples, particle surfaces may be functionalized and may require activation prior to attachment. In other examples, particle surfaces may be activated prior to functionalization, at which time a Molecular Net may be attached. Yet in other examples, Molecular Nets may be constructed directly on the particle surface.
Attachment of Molecular Nets to a particle may change the physical and/or chemical features of said particle. In some examples, Molecular Nets may comprise pseudorandom topological features placed on the surface of a particle. In some examples, Molecular Net particles may comprise topological features, the topological features comprising capture molecules and linkers and may also comprise spacers. Examples of various topological features may include appendages, spikes, plateaus, planes, mounds, fissures, pellicles, stipples, channels, pores and other and may be comprised of capture components directly linked within and/or linked to one or more layer of a Molecular Net.
Attachment of Molecular Nets to a particle may change the physical and/or chemical features of said particle. In some examples, Molecular Nets may comprise pseudorandom topological features placed on the surface of a particle. In some examples, Molecular Net particles may comprise topological features, the topological features comprising capture molecules and linkers and may also comprise spacers. Examples of various topological features may include appendages, spikes, plateaus, planes, mounds, fissures, pellicles, stipples, channels, pores and other and may be comprised of capture components directly linked within and/or linked to one or more layer of a Molecular Net.
[0047] Other examples of topological features may comprise be pockets, pillars, bumps, branches, projections, ridges, clefts, trellis-like structures, flakes, pellets, spheres, or others.
Topological features may be pre-formed in solution and linked to the Molecular Net or may be formed at the time each layer is constructed.
Topological features may be pre-formed in solution and linked to the Molecular Net or may be formed at the time each layer is constructed.
[0048] Molecular Nets on particles may comprise heterogeneous capture molecules within one or more layer of a Molecular Net. Benefits of a heterogeneous design may relate to the capture of a plurality of analytes having a plurality of surface chemistries on a single particle.
Heterogeneous capture molecules incorporated into a Molecular Net during fabrication may be randomly distributed throughout each layer; may be stratified throughout each layer; or other, depending on use.
Heterogeneous capture molecules incorporated into a Molecular Net during fabrication may be randomly distributed throughout each layer; may be stratified throughout each layer; or other, depending on use.
[0049] Molecular Nets may be attached to particles to increase surface area of said particle. Molecular Nets may also be used to increase particle diameter.
Topological features of a Molecular Net on a particle may relate to an increased particle size in addition to analyte capture capacity.
Topological features of a Molecular Net on a particle may relate to an increased particle size in addition to analyte capture capacity.
[0050] In some examples, a first layer of Molecular Net may be attached to a particle surface to modify the physical and/or chemical properties of particle. In many commercial particles, "bead effects" or "surface effects" can hamper results and are still not well understood.
Traditional conjugation techniques that result in 2D conjugates and 2D
conjugated surfaces often suffer from surface effects. Molecular Nets may be used to minimize or neutralize bead effects to minimize non-specific binding to a bead surface, bead autofluorescence, bead interference with in an assay or other. In some examples, Molecular Net particles may impart increased analyte binding capacity and may also impart blockade of non-specific binding of undesired analytes to increase the signal-to-noise ratio in an assay, yield and purity of purified analyte or other.
Traditional conjugation techniques that result in 2D conjugates and 2D
conjugated surfaces often suffer from surface effects. Molecular Nets may be used to minimize or neutralize bead effects to minimize non-specific binding to a bead surface, bead autofluorescence, bead interference with in an assay or other. In some examples, Molecular Net particles may impart increased analyte binding capacity and may also impart blockade of non-specific binding of undesired analytes to increase the signal-to-noise ratio in an assay, yield and purity of purified analyte or other.
[0051] In some examples In yet another aspect, the invention features molecular Net on particle containing more than one layer, wherein each layer contains capture molecules directed against analyte, wherein each layer contains distinct capture molecules directed against distinct analyte, wherein different layers can be directed against different analytes to enable the capture of analyte or a plurality of analytes.
[0052] In yet another aspect, a Molecular Net placed on a solid phase surface may be used to increase the purity of one or more analyte recovered from a sample.
Molecular Net-coated surfaces may reduce non-specific binding of undesired analyte compared to commercial 2D functionalized surfaces.
Molecular Net-coated surfaces may reduce non-specific binding of undesired analyte compared to commercial 2D functionalized surfaces.
[0053] In some examples, Molecular Nets placed on particles may significantly increase analyte capture capacity of a particle. Additional layering of a Molecular Net may further increase the number of bound analyte per particle and may be used to enhance recovery or yield of analyte from a sample and may be used to deplete one or more analyte from a sample.
Advantages of using Molecular Nets
Advantages of using Molecular Nets
[0054] Molecular and cellular testing strategies employ the use of single-plex or multi-plex immunoassays, PCR assays, next-generation sequencing techniques or other to identify the presence of or to measure the amount of one or more analyte in a sample.
[0055] In multiplexed assays, reactions may be separated spatially or may be combined into a single testing reaction and may employ solid phases comprising unique identifiers to provide information. Some examples of unique identifiers may comprise the use of different barcodes, different fluorescence emissions, different chemistries, different ordered nucleotide tags, or other.
[0056] Solid phases may be used in single-plex and multi-plex assays may rely on the specific binding of target analyte to produce a measurable signal or a measurable change in signal and may be used in a direct assay or may be used in an indirect assay.
Measurable signals may be generated from a positive test and may comprise electric, thermal, magnetic, optical, vibrational, isotopic, or other measurable characteristic.
Measurable signals may be generated from a positive test and may comprise electric, thermal, magnetic, optical, vibrational, isotopic, or other measurable characteristic.
[0057] Many of the difficulties in achieving sensitive and reproducible measurements using current strategies result in high non-specific binding, lower sensitivity, low signal-to-noise and thereby require upstream sample processing steps to remove as many non-specific components from a sample, coupled with the use of highly sensitive reader technologies and complex algorithms which may be required in order to determine real signal from the noise, which make them difficult to translate to truly real-time, easy-to-use molecular diagnostics and analyte measurement tools.
[0058] Molecular Nets may be used in place of current commercial approaches and may generate specific and sensitive analyte capture, detection and measurement from a sample.
Examples of results obtained from the use of Molecular Nets in place of current approaches for analyte capture are presented in Figures 1-6. Improvements in assay sensitivity, minimum levels of analyte detection, and other features may be obtained through the use of a Molecular Net in place of current 2D approaches for analyte capture and measurement. Reduction in background noise may be obtained through the use of a Molecular Net in place of current 2D approaches and may be used to improve analyte purification, analyte purity, and assay sensitivity.
Examples of results obtained from the use of Molecular Nets in place of current approaches for analyte capture are presented in Figures 1-6. Improvements in assay sensitivity, minimum levels of analyte detection, and other features may be obtained through the use of a Molecular Net in place of current 2D approaches for analyte capture and measurement. Reduction in background noise may be obtained through the use of a Molecular Net in place of current 2D approaches and may be used to improve analyte purification, analyte purity, and assay sensitivity.
[0059] Advantages of a Molecular Net are presented in Table 4 and may include: the rapid capture of one, several or a plurality of molecular and cellular analytes in a raw sample;
ability to generate sensitive and specific signals when used in a test involving indirect and direct detection methods; ability to generate a signal having enhanced fluorescent intensity; ability to concentrate bound analyte; ability to spatially separate bound analyte in a manner that reduces stearic hindrance between analytes and/or between detection molecules;
enhanced stability;
reduced background and others.
TABLE 4. Demonstrated Advantages of Molecular Nets Demonstrated Advantages Anticipated Impact Finger stick by lancet (-50 uL) Displaces the need for venipuncture No sample prep ¨ compatible with raw, Displaces the need for sample processing ¨ both unprocessed sample centrifugation & serum isolation (saves time) Point-of-use testing Displaces the need and cost of sample transport, with ultimate potential for testing at home or in field settings Portability, no complex capital equipment Displaces the need and cost for off-site CLIA
labs Provides immediate answers (<30 mins) Enables point-of-care treatment and patient monitoring Multiplexing (multi-analyte analysis) Delivers more robust answer and eliminates the cost of having to run separate tests per sample Simple test procedure Displaces the need for high-complexity testing (Western blot, Luminex, bead arrays, and PCR) Capable of producing simple actionable Enables health care provider (and/or ultimately readouts (Binary-No/Yes; Semi- the patient) to make decision sooner;
flexible data quantitative-Low, Mid, High; Fully output enables numerous applications quantitative) Stability of test (enzyme-free) = longer Increases shelf life, & reduces costs associated shelf life with storage issues Cost effective Disposable cassette with the potential for multiple-tests-in-1 High signal, very low noise (demonstrated Significantly more sensitive than current femtogram range in multiple test types) immunoassays Molecular Nets and their Use
ability to generate sensitive and specific signals when used in a test involving indirect and direct detection methods; ability to generate a signal having enhanced fluorescent intensity; ability to concentrate bound analyte; ability to spatially separate bound analyte in a manner that reduces stearic hindrance between analytes and/or between detection molecules;
enhanced stability;
reduced background and others.
TABLE 4. Demonstrated Advantages of Molecular Nets Demonstrated Advantages Anticipated Impact Finger stick by lancet (-50 uL) Displaces the need for venipuncture No sample prep ¨ compatible with raw, Displaces the need for sample processing ¨ both unprocessed sample centrifugation & serum isolation (saves time) Point-of-use testing Displaces the need and cost of sample transport, with ultimate potential for testing at home or in field settings Portability, no complex capital equipment Displaces the need and cost for off-site CLIA
labs Provides immediate answers (<30 mins) Enables point-of-care treatment and patient monitoring Multiplexing (multi-analyte analysis) Delivers more robust answer and eliminates the cost of having to run separate tests per sample Simple test procedure Displaces the need for high-complexity testing (Western blot, Luminex, bead arrays, and PCR) Capable of producing simple actionable Enables health care provider (and/or ultimately readouts (Binary-No/Yes; Semi- the patient) to make decision sooner;
flexible data quantitative-Low, Mid, High; Fully output enables numerous applications quantitative) Stability of test (enzyme-free) = longer Increases shelf life, & reduces costs associated shelf life with storage issues Cost effective Disposable cassette with the potential for multiple-tests-in-1 High signal, very low noise (demonstrated Significantly more sensitive than current femtogram range in multiple test types) immunoassays Molecular Nets and their Use
[0060] Molecular Nets may be used in applications where analyte binding efficiency, analyte binding kinetics, analyte binding capacity, analyte detection, analyte measurement, analyte enrichment, analyte purification and analyte delivery may be important. Molecular Nets may be used in fluid phase or may be attached to a solid phase.
[0061] Molecular Nets may be attached through absorption or covalent processes on a receptive surface. Examples of solid phases include but are not limited to nanotubes, metals, particles, microtiter plates, slides, cassettes, probes, lateral flow tests, stents, catheters, valves, blood tubes, needles, solid phase devices or other. Examples of chemistries of various solid phases that may be compatible for Molecular Net attachment include but are not limited to plastics, other polymer, thin film, colloidal metals, silica, carbon nanotube, protein, carbohydrate, lipid, nucleic acid, cell, tissue or other.
[0062] Molecular Nets may be attached to a solid phase device surface to capture, purify or deplete one or more analyte from a sample. An example of using a Molecular Net for analyte capture and/or purification from a sample is presented in Figure 1. Some other examples of Molecular Nets that may be used to capture and purify analyte from a sample are: Protein A, Protein G or Protein L Net-coated microspheres for immunoglobulin capture;
Streptavidin Net-coated microspheres for biotin capture; TNF Net-coated microspheres for anti-TNF biologic capture; IL6 Net-coated microspheres for anti-1L6 biologic capture; IgM Net-coated microspheres for RNA virus capture; Ig Fe Net-coated microspheres for complement capture;
antigen Net-coated microspheres for antigen-specific immunoglobulin; antigen-specific immune cell capture; and others. Molecular Nets may be used in chromatography methods for the capture and purification of one or more analyte from a sample.
Streptavidin Net-coated microspheres for biotin capture; TNF Net-coated microspheres for anti-TNF biologic capture; IL6 Net-coated microspheres for anti-1L6 biologic capture; IgM Net-coated microspheres for RNA virus capture; Ig Fe Net-coated microspheres for complement capture;
antigen Net-coated microspheres for antigen-specific immunoglobulin; antigen-specific immune cell capture; and others. Molecular Nets may be used in chromatography methods for the capture and purification of one or more analyte from a sample.
[0063] Molecular Nets may be used to capture analyte from a sample for downstream analyte measurement by an independent method, referred to herein as sample prep. Examples of independent methods may include mass spectrometry, immunoassay, PCR, next-generation sequencing, qRT-PCR, digital PCR, microscopy, fluorescence, flow cytometry, bead cytometry, or other.
[0064] In another aspect, the invention improves signal-to-noise ratios when used in an assay.
[0065] Molecular Nets may be attached to a solid phase device surface to measure the presence, absence, modification or concentration of one or more analyte.
Examples of using Molecular Nets for analyte detection and/or measurement are presented in Figures 3 and 4. In some other examples, Molecular Nets may be used to simultaneous detect and measure 2 or more specific analytes in a direct or indirect manner. Indirect capture by a Molecular Net may relate to the capture of a primary analyte by a specific capture molecule of a Molecular Net that may enable the detection of one or more related secondary associated with the captured primary analyte. Molecular Nets may be used as discovery tools capture primary analytes from a sample and enables the identification, detection or measurement of secondary analytes that are captured-by-association. Molecular Nets may be used in this manner for drug discovery, pathway mapping, and in proteomics, transcriptomics, glycomics, lipidomics, metabolomics, functional genomics, foodomics, nutrition, pharmacology, toxicology and others.
Examples of using Molecular Nets for analyte detection and/or measurement are presented in Figures 3 and 4. In some other examples, Molecular Nets may be used to simultaneous detect and measure 2 or more specific analytes in a direct or indirect manner. Indirect capture by a Molecular Net may relate to the capture of a primary analyte by a specific capture molecule of a Molecular Net that may enable the detection of one or more related secondary associated with the captured primary analyte. Molecular Nets may be used as discovery tools capture primary analytes from a sample and enables the identification, detection or measurement of secondary analytes that are captured-by-association. Molecular Nets may be used in this manner for drug discovery, pathway mapping, and in proteomics, transcriptomics, glycomics, lipidomics, metabolomics, functional genomics, foodomics, nutrition, pharmacology, toxicology and others.
[0066] In some examples, Molecular Nets may be used to detect drug resistance in a cell.
Cells may be tumor cells, immune cells, microbial cells or other cells.
Molecular Nets for these applications may comprise capture molecules directed against one or more unique features of a cell type. Molecular Nets may additionally be fabricated in a manner to impart surface topology relating to the capture of in tact cells.
Cells may be tumor cells, immune cells, microbial cells or other cells.
Molecular Nets for these applications may comprise capture molecules directed against one or more unique features of a cell type. Molecular Nets may additionally be fabricated in a manner to impart surface topology relating to the capture of in tact cells.
[0067] In other examples, Molecular Nets may be fabricated and used in:
immune cell reactivity measurement; immune response monitoring; immune response classification;
immunoglobulin titering; biotinylated molecule capture; multiplex immunoassays; singleplex immunoassays; next-generation sequencing reactions; PCR; microbiome capture;
microbiome discovery; mRNA and encoded protein measurement; SNP (single nucleotide polymorphisms) mapping; SNP detection; disease marker sample preparation; miRNA capture and/or measurement; post-translation modification discovery and/or capture and/or measurement;
kinase activity measurement; or other.
immune cell reactivity measurement; immune response monitoring; immune response classification;
immunoglobulin titering; biotinylated molecule capture; multiplex immunoassays; singleplex immunoassays; next-generation sequencing reactions; PCR; microbiome capture;
microbiome discovery; mRNA and encoded protein measurement; SNP (single nucleotide polymorphisms) mapping; SNP detection; disease marker sample preparation; miRNA capture and/or measurement; post-translation modification discovery and/or capture and/or measurement;
kinase activity measurement; or other.
[0068] Molecular Nets may have measurable characteristics imparted during the fabrication process and may be used in a direct or indirect manner as a sensor. A measurable change in one or more characteristic of a Molecular Net sensor may be detected using commercial approaches employing the use of optical sensing, electrochemical sensing, electromagnetic sensing, electrical impedence, or other. In one example, a Molecular Net sensor may be used to capture and bind an analyte. Analyte binding may result in a measurable change in a characteristic of a Molecular Net sensor. A binding event or modifying event pertaining to the Molecular Net sensor may be monitored over a period of time, and the changes in Molecular Net sensor characteristics may be detected, relayed and collected by a device.
Other examples of using a Molecular Net as a sensor may include an analyte binding event, enzymatic reaction, analyte modification event, cell differentiation, cell-cell interaction, or other.
Other examples of using a Molecular Net as a sensor may include an analyte binding event, enzymatic reaction, analyte modification event, cell differentiation, cell-cell interaction, or other.
[0069] Examples of measurable characteristics include but are not limited to: physical shape, height, density, fluorescence intensity, wavelength shift (FRET or FRAP), vibrational frequency, absorbance, flexibility, refractiveness, conductance, impedence, resistance, melting temperature, denaturation temperature, freezing temperature, and other.
[0070] Measuring devices that may be compatible for use with a Molecular Net sensor may comprise: photonic multichannel analyzers, spectrometers, magnetic resonance imagers, magnetic field detectors, optical fibers, glass pipettes, circuits, fluorometers, spectroscopic analyzers, flow cytometers, CCD cameras, microscopes, acoustic chambers, microphones, luminometers, and other. The measuring devices may be used to measure changes in: thickness, topology, charge, insulation, capacitance, voltage, color, acoustics, vibration, magnetism, enzymatic activity or other characteristics of a Molecular Net used as a sensor.
[0071] Additionally, Molecular Nets may be used in flexible circuits, whereby the capture molecules and/or structural molecules may be connected to conductive molecules.
Molecular Net circuits may be used in single-sided flexible circuits, double access (back bared flex circuits), sculptured flex circuits, double-sided flex circuits, multilayered flex circuits, ridge flex circuits, ridge-flex boards, polymer thick film flex circuits or other.
Most flexible circuits are passive wiring structures that are used to interconnect electronic components such as integrated circuits, resistor, capacitors and the like, however some are used only for making interconnections between other electronic assemblies either directly or by means of connectors.
Molecular Nets for use in circuits or for use as a component of a circuit may be comprised of synthetic components or may be comprised of biochemical capture molecules and/or cells and may be fabricated in a manner to be used in a flexible circuit. Molecular Net circuits may also be used as a sensor.
Molecular Net circuits may be used in single-sided flexible circuits, double access (back bared flex circuits), sculptured flex circuits, double-sided flex circuits, multilayered flex circuits, ridge flex circuits, ridge-flex boards, polymer thick film flex circuits or other.
Most flexible circuits are passive wiring structures that are used to interconnect electronic components such as integrated circuits, resistor, capacitors and the like, however some are used only for making interconnections between other electronic assemblies either directly or by means of connectors.
Molecular Nets for use in circuits or for use as a component of a circuit may be comprised of synthetic components or may be comprised of biochemical capture molecules and/or cells and may be fabricated in a manner to be used in a flexible circuit. Molecular Net circuits may also be used as a sensor.
[0072] In some examples, Molecular Net circuits may have specific electrochemical properties and may be used to monitor various parameters such as pH, current, voltage, impedence, or other in an electrochemical/electrolyte cell. Binding events and modifying events that may occur to Molecular Net may be measurable and may be reflected by a change in the conductance, current, or voltage. More specifically, the introduction of a sample containing an analyte that has specific binding affinity for, or is reactive towards, a component in a Molecular Net circuit may be monitored by a change in the electrochemical properties of the Molecular Net and/or the surrounding environment.
[0073] Examples of binding events on a Molecular Net used in a circuit may include:
antibody-antigen interaction, nucleic acid-nucleic acid interaction, enzyme-substrate interaction, drug-target interaction, enzyme-co-factor interaction, ligand-cell interaction, or any other specific surface-chemistry-driven non-covalent interaction. Analyte capture by a Molecular Net may be determined by a change in pH, current or voltage an electrochemical/electrolyte cell.
Measurement of a change in Molecular Net characteristics may also result from one or more, or an accumulation of modifying events to one or more component in a Molecular Net or to a capture analyte. Examples of modifying events may include: enzyme cleavage;
post-translational modification (such as phosphorylation, sulfonation, glycosylation, methylation, or other); removal of a post-translational modification (such as de-phosphorylation); or other similar modification. Modifying events may be determined by a change in pH, current or voltage in the electrochemical/electrolyte cell resulting from a change in Molecular Net characteristics or in the surrounding buffer system.
antibody-antigen interaction, nucleic acid-nucleic acid interaction, enzyme-substrate interaction, drug-target interaction, enzyme-co-factor interaction, ligand-cell interaction, or any other specific surface-chemistry-driven non-covalent interaction. Analyte capture by a Molecular Net may be determined by a change in pH, current or voltage an electrochemical/electrolyte cell.
Measurement of a change in Molecular Net characteristics may also result from one or more, or an accumulation of modifying events to one or more component in a Molecular Net or to a capture analyte. Examples of modifying events may include: enzyme cleavage;
post-translational modification (such as phosphorylation, sulfonation, glycosylation, methylation, or other); removal of a post-translational modification (such as de-phosphorylation); or other similar modification. Modifying events may be determined by a change in pH, current or voltage in the electrochemical/electrolyte cell resulting from a change in Molecular Net characteristics or in the surrounding buffer system.
[0074] Methods to determine changes in electrochemical properties of a Molecular Net used in a circuit may include the use of scanning ion current microscopy, nanofluidic diodes, nanopores or nanochannels that display voltage-gated ion current, ion nanogating, nanopore-based sensing platforms and other methods for measuring the flow, or changes in flow of electrical charge through a medium. More specifically, the inherent sensitivity of many solid-state nanopore sensors is the selective permeability of electrolytes, or ion current, when a bias is applied across the nanopore. Molecular Nets may be coated onto the surface of a nanopore and the change in current, voltage, and impedance can be monitored.
[0075] Molecular Net can also be coated onto the surface of a carbon nanotube and whereby the molecular Net can be constructed in a manner to generate size exclusion and affinity requirements for analyte sensing.
[0076] Bio-Layer Interferometry (BLI) is a label-free technology for measuring biomolecular interactions. It is an optical analytical technique that analyzes the interference pattern of white light reflected from two surfaces: a layer of immobilized molecular Net on the biosensor tip, and an internal reference layer. Any change in the number of molecules bound to the biosensor tip causes a shift in the interference pattern that can be measured in real-time. The binding between a ligand immobilized on the molecular Net-coated biosensor tip and an analyte in solution produces an increase in optical thickness at the biosensor tip, which results in a wavelength shift, AX, which is a direct measure of the change in thickness of the biological layer.
Interactions may be measured in real time, providing the ability to monitor binding specificity, rates of association and dissociation, or concentration, with precision and accuracy. Only molecules binding to or dissociating from the Molecular Net biosensor may shift the interference pattern and generate a response profile. Unbound molecules, may change the refractive index of the surrounding medium, or may change flow rate but will not affect the interference pattern.
This is a unique characteristic of BLI and extends its capability to perform in crude samples used in applications for analyte - capture molecule binding, quantitation, affinity, and kinetics.
Interactions may be measured in real time, providing the ability to monitor binding specificity, rates of association and dissociation, or concentration, with precision and accuracy. Only molecules binding to or dissociating from the Molecular Net biosensor may shift the interference pattern and generate a response profile. Unbound molecules, may change the refractive index of the surrounding medium, or may change flow rate but will not affect the interference pattern.
This is a unique characteristic of BLI and extends its capability to perform in crude samples used in applications for analyte - capture molecule binding, quantitation, affinity, and kinetics.
[0077] Molecular Net particles may also be used to deliver an active agent. Active agents may be pre-loaded onto capture molecules located in one or more layer of a Molecular Net. Active agents may comprise: drugs, therapeutics, toxins, viruses, allergens, vaccine components, antigens, immune modulators, surfactants, microbes, oligonucleotides, nutrients, or other. Molecular Net particles may be used in drug or therapeutic delivery, vaccine delivery, in biofermentation or other. Molecular Nets may comprise one or more targeting agent on a surface-exposed layer to facilitate specificity in targeting said Molecular Net particle to a specific cell type, tissue type, organ type or other. Targeting agents may be capture molecules of a Molecular Net. Targeting agents may comprise: antibodies, receptors, ligands, anti-ligands, or other. Targeting agents in a Molecular Net may be covalently linked to capture molecules, linkers, and spacers in a surface-exposed layer. Targeting agents may also contribute to the topological features of a Molecular Net.
EXAMPLES
Example 1. Comparison of Conventional 2D and 3D Molecular Net microparticles for analyte purification.
EXAMPLES
Example 1. Comparison of Conventional 2D and 3D Molecular Net microparticles for analyte purification.
[0078] Molecular Nets comprised of monomeric protein G and linked protein G and crosslinkers BS3, EMCS, EGS, BMPH and others were used in fabrication.
Molecular Net fabrication occurred in real-time on 0.8-10 um magnetic polystyrene microparticle and 45 um nitrocellulose microparticle surfaces. In some examples, the capture molecule, protein G was used as the only source of structural support. In some examples, pre-linked protein G and monomeric protein G were mixed to serve as additional structural support for fabrication of some layers of the Molecular Net. Yet in some other examples, a first layer of Molecular Net comprised protein G and Ig Fc region to serve as structural support for fabrication of additional layers of the Molecular Net. In some examples, a protein G Molecular Net comprised 2 layers and in other examples, a protein G Molecular Net comprised 3 layers. The last layer of the Molecular Net comprised topological features to enhance analyte (in this case IgG) binding and recovery from a sample. Figure 1 is an example of data obtained using protein G Molecular Net microparticles in comparison to commercial protein G microparticles. Briefly, IgG-Alexa 647 was spiked into human serum (1 ug/tube). Uncoated microparticles, commercial protein G
microparticles and protein G Molecular Net microparticles were incubated with spiked sample for 15-60 min at RT (at 100,000 particles (uncoated control), 100,000 particles (commercial) and 25,000 particles (Molecular Net). Particles were isolated from samples using magnetic separation and were washed 3x in PBST. Particles were resuspended in 2xLSB, boiled and loaded onto an SDS-PAGE. Recovered IgG was measured by Coomassie-stained band densitometry compared to input control. Depicted in Figure 1 is the percent recovery of input for each purification type. Use of an optimized Molecular Net can reduce background noise in an assay and increase a visible signal.
Example 2. Effectiveness of Conventional 2D Conjugates for analyte detection.
Molecular Net fabrication occurred in real-time on 0.8-10 um magnetic polystyrene microparticle and 45 um nitrocellulose microparticle surfaces. In some examples, the capture molecule, protein G was used as the only source of structural support. In some examples, pre-linked protein G and monomeric protein G were mixed to serve as additional structural support for fabrication of some layers of the Molecular Net. Yet in some other examples, a first layer of Molecular Net comprised protein G and Ig Fc region to serve as structural support for fabrication of additional layers of the Molecular Net. In some examples, a protein G Molecular Net comprised 2 layers and in other examples, a protein G Molecular Net comprised 3 layers. The last layer of the Molecular Net comprised topological features to enhance analyte (in this case IgG) binding and recovery from a sample. Figure 1 is an example of data obtained using protein G Molecular Net microparticles in comparison to commercial protein G microparticles. Briefly, IgG-Alexa 647 was spiked into human serum (1 ug/tube). Uncoated microparticles, commercial protein G
microparticles and protein G Molecular Net microparticles were incubated with spiked sample for 15-60 min at RT (at 100,000 particles (uncoated control), 100,000 particles (commercial) and 25,000 particles (Molecular Net). Particles were isolated from samples using magnetic separation and were washed 3x in PBST. Particles were resuspended in 2xLSB, boiled and loaded onto an SDS-PAGE. Recovered IgG was measured by Coomassie-stained band densitometry compared to input control. Depicted in Figure 1 is the percent recovery of input for each purification type. Use of an optimized Molecular Net can reduce background noise in an assay and increase a visible signal.
Example 2. Effectiveness of Conventional 2D Conjugates for analyte detection.
[0079] Traditional approaches to covalently link capture antibody to a surface is a 2-dimensional approach (X and Y planes). as there are no additional layers added onto the surface of the linked antibodies on a surface. Traditional methods used to covalently link capture antibody to a surface involve a single type of linker, for example EDC, NHS, sulfo-NHS or other. Occasionally, a second linker is used to secure the capture antibody to a surface, but involves removal of the first linker and does not add additional height or layering to the antibody-conjugated surface. In an example, per manufacturer instructions, anti-human neuroserpin antibody was coupled to Luminex particles (bead region #54) by linker. Particles were then quenched, blocked, and washed prior to use. Particles were incubated for 15 min in pre-cleared serum + neuroserpin at a concentration range of (0-1 ng/mL). Bound particles were washed and incubated with biotin-anti-Neuroserpin (10 ng/mL) for 15 min.
Neuroserpin detection was visualized by avidin-PE (30 ng/mL) for 15 min. Washed particles were then analyzed on a Luminex 100, collecting 100 particles per sample. Presented in Figure 2 is the median fluorescence intensity (Fl) at each dilution above background fluorescence intensity.
FIG. 3. Effectiveness of Molecular Net microparticles in measuring analyte.
Neuroserpin detection was visualized by avidin-PE (30 ng/mL) for 15 min. Washed particles were then analyzed on a Luminex 100, collecting 100 particles per sample. Presented in Figure 2 is the median fluorescence intensity (Fl) at each dilution above background fluorescence intensity.
FIG. 3. Effectiveness of Molecular Net microparticles in measuring analyte.
[0080] Molecular Net comprised of identical anti-human neuroserpin antibody (as Figure 2) and linkers Sulfo-NHS, EMCS, EGS, BMPH and others was fabricated to provide a 3-dimensional multi-layered (X, Y, and Z planes) matrix. The Molecular Nets were then covalently linked to Luminex microparticles (bead region #54). Assay performance with the 4-layered Molecular Nets are presented in Figure 3. Improved assay MFI was observed using a 3-dimensional multi-layered Molecular Net.
FIG. 4. Effectiveness of a Molecular Net with topology in measuring analyte.
FIG. 4. Effectiveness of a Molecular Net with topology in measuring analyte.
[0081] Molecular Net comprised of identical anti-human neuroserpin antibody (as Figures 2 and 3) and linkers Sulfo-NHS, EMCS, EGS, BMPH and others was fabricated to provide a 3-dimensional multi-layered (X, Y, and Z planes) matrix. The Molecular Nets were then covalently linked to Luminex microparticles (bead region #54). Assay performance with the 5-layered Molecular Nets are presented in Figure 4. Improved assay MFI was observed using a 3-dimensional multi-layered Molecular Net with enhanced topology in the outer layers.
FIG. 5. Comparison of traditionally conjugated microparticles and Molecular Net microparticles in an ELISA.
FIG. 5. Comparison of traditionally conjugated microparticles and Molecular Net microparticles in an ELISA.
[0082] Molecular Nets comprised of monoclonal antibody directed against human-TauF
and crosslinkers Sulfo-NHS, EMCS, EGS, BMPH and others were used in fabrication.
Molecular Net fabrication occurred in real-time on 0.5, 6.3 and 10 um magnetic microparticle surfaces. In some examples, the capture molecule, anti-Tau mAb, was used as the only source of structural support. In some examples, the spacer, albumin, was mixed with the anti-Tau mAb in a first layer at a 1.5:1.0 Molar ratio (albumin:anti-Tau Ab) to serve as additional structural support for fabrication of the first layer. In some examples, a second capture molecule, human tubulin was used and provided both structural support and capture roles within a Molecular Net. Figure 5 is an example of data obtained using an anti-Tau Molecular Net (LV.P6 Cap-TECH) in comparison to a commercial Tau microparticle (Partner LV) ELISA (identical assay conditions, identical antibody pair, etc.). Figure 5 is an example of using a Molecular Net to reduce background noise in an assay and increase a visible signal in an ELISA.
FIG. 6. Comparison of traditionally conjugated microparticles and Molecular Net microparticles using Luminex.
and crosslinkers Sulfo-NHS, EMCS, EGS, BMPH and others were used in fabrication.
Molecular Net fabrication occurred in real-time on 0.5, 6.3 and 10 um magnetic microparticle surfaces. In some examples, the capture molecule, anti-Tau mAb, was used as the only source of structural support. In some examples, the spacer, albumin, was mixed with the anti-Tau mAb in a first layer at a 1.5:1.0 Molar ratio (albumin:anti-Tau Ab) to serve as additional structural support for fabrication of the first layer. In some examples, a second capture molecule, human tubulin was used and provided both structural support and capture roles within a Molecular Net. Figure 5 is an example of data obtained using an anti-Tau Molecular Net (LV.P6 Cap-TECH) in comparison to a commercial Tau microparticle (Partner LV) ELISA (identical assay conditions, identical antibody pair, etc.). Figure 5 is an example of using a Molecular Net to reduce background noise in an assay and increase a visible signal in an ELISA.
FIG. 6. Comparison of traditionally conjugated microparticles and Molecular Net microparticles using Luminex.
[0083] Molecular Net comprised of monoclonal antibody directed against human-thyroid stimulating hormone and crosslinkers EDC, BS(PEG)9, EMCS, EGS, BMPH and others were used in fabrication. Molecular Net fabrication occurred in real-time on Luminex magnetic microparticle surfaces. In some examples, the capture molecule, anti-TSH mAb, was used as the only source of structural support. In some examples, the spacers, PEG, heat-denatured lysozyme and others were mixed with the anti-TSH mAb in a first layer at a 1.0:2.0 Molar ratio (spacer:anti-TSH Ab) to serve as additional structural support for fabrication of the first layer. In some examples, an anti-TSH Molecular Net comprised 4 layers and in other examples, an anti-TSH Molecular Net comprised 6 layers with the last layer comprising topological features to enhance analyte binding and performance in a Luminex. Figure 6A is an example of using a Molecular Net to increase the overall MFI in a Luminex assay. Figure 6B is exemplary data obtained in a Luminex assay to increase the minimum levels of detection in a Luminex assay.
FIG. 7. Exemplary Molecular Nets on particles.
FIG. 7. Exemplary Molecular Nets on particles.
[0084] Figure 7 depicts some examples in which Molecular Nets may be placed onto a particle surface. In some examples, a Molecular Net is placed on a particle surface (Fig. 7A, 1001) in a circumferential manner whereby a Molecular Net having X, Y and Z
spatial orientation may be fairly symmetrical and where each layer (examples of 3 layers, 1002, 1003 and 1004) adds to the Z plane of the particle. In some examples, Molecular Nets may be placed onto a particle surface (Fig. 7B, 1005) in an asymmetrical manner whereby a Molecular Net having X, Y and Z spatial orientation may be placed onto the surface of a particle in a manner to generate a polarity of the particle and where each layer (examples of 3 layers, 1006, 1007 and 1008) adds to the Z plane of the particle in a layer-dependent manner (for example, some layers may have less height and other layers may have more height). In other examples, Molecular Nets may be placed onto a portion of particle surface (Fig. 7C, 1009) in an asymmetrical manner whereby a Molecular Net having X, Y and Z spatial orientation may be placed onto the surface of a particle in a manner to generate a polarity of the particle and where each layer (examples of 3 layers, 1010, 1011 and 1012) adds to the Z plane of the particle in a layer-dependent manner (for example, some layers may have specificity for an analyte and other layers may have specificity for other analytes).
FIG. 8. Exemplary Molecular Net topological features on particles.
spatial orientation may be fairly symmetrical and where each layer (examples of 3 layers, 1002, 1003 and 1004) adds to the Z plane of the particle. In some examples, Molecular Nets may be placed onto a particle surface (Fig. 7B, 1005) in an asymmetrical manner whereby a Molecular Net having X, Y and Z spatial orientation may be placed onto the surface of a particle in a manner to generate a polarity of the particle and where each layer (examples of 3 layers, 1006, 1007 and 1008) adds to the Z plane of the particle in a layer-dependent manner (for example, some layers may have less height and other layers may have more height). In other examples, Molecular Nets may be placed onto a portion of particle surface (Fig. 7C, 1009) in an asymmetrical manner whereby a Molecular Net having X, Y and Z spatial orientation may be placed onto the surface of a particle in a manner to generate a polarity of the particle and where each layer (examples of 3 layers, 1010, 1011 and 1012) adds to the Z plane of the particle in a layer-dependent manner (for example, some layers may have specificity for an analyte and other layers may have specificity for other analytes).
FIG. 8. Exemplary Molecular Net topological features on particles.
[0085] Figure 8 depicts some examples in which Molecular Nets may be placed onto a particle surface. In some examples, a Molecular Net is placed on a particle surface (Fig. 8A, 2001) in a circumferential manner whereby a Molecular Net having X, Y and Z
spatial orientation may be fairly symmetrical in one layer (2002) and where each layer (examples of 3 layers, 2002, 2003 and 2004) adds to the Z plane of the particle in differing and asymmetric ways (for example, topology is generated). In some examples, Molecular Nets may be placed onto a particle surface (Fig. 8B, 2005) in an asymmetrical manner whereby a Molecular Net having X, Y and Z spatial orientation may be placed onto the surface of a particle in a manner to generate structural features (2008) throughout layers 1 (2006), 2 (2007) and 3 (2008) of the particle and where each layer adds to the Z plane of the particle in a layer-dependent manner (for example, some layers may have less height and other layers may have more height).
Additionally, the structural elements in each layer may also serve an analyte capture role in a Molecular Net. In other examples, Molecular Nets may be placed onto a portion of particle surface (Fig. 8C, 1009) in an asymmetrical manner whereby a Molecular Net having X, Y and Z
spatial orientation may be placed onto the surface of a particle in a manner to generate a polarity of the particle and where each layer (examples of 4 layers, 2010, 2011, 2012 and 2013) adds to the Z plane of the particle in a layer-dependent manner and whereby each layer may serve both structural and analyte capture roles. For example, some layers may have specificity for an analyte based on size (e.g., Fig. 8C, 2010) and outer layers (e.g., Fig. 8C, 2013) may have specificity for analyte of a larger size.
FIG. 9. Exemplary Molecular Nets for analyte delivery.
spatial orientation may be fairly symmetrical in one layer (2002) and where each layer (examples of 3 layers, 2002, 2003 and 2004) adds to the Z plane of the particle in differing and asymmetric ways (for example, topology is generated). In some examples, Molecular Nets may be placed onto a particle surface (Fig. 8B, 2005) in an asymmetrical manner whereby a Molecular Net having X, Y and Z spatial orientation may be placed onto the surface of a particle in a manner to generate structural features (2008) throughout layers 1 (2006), 2 (2007) and 3 (2008) of the particle and where each layer adds to the Z plane of the particle in a layer-dependent manner (for example, some layers may have less height and other layers may have more height).
Additionally, the structural elements in each layer may also serve an analyte capture role in a Molecular Net. In other examples, Molecular Nets may be placed onto a portion of particle surface (Fig. 8C, 1009) in an asymmetrical manner whereby a Molecular Net having X, Y and Z
spatial orientation may be placed onto the surface of a particle in a manner to generate a polarity of the particle and where each layer (examples of 4 layers, 2010, 2011, 2012 and 2013) adds to the Z plane of the particle in a layer-dependent manner and whereby each layer may serve both structural and analyte capture roles. For example, some layers may have specificity for an analyte based on size (e.g., Fig. 8C, 2010) and outer layers (e.g., Fig. 8C, 2013) may have specificity for analyte of a larger size.
FIG. 9. Exemplary Molecular Nets for analyte delivery.
[0086] Figure 9 depicts some examples in which Molecular Nets may be placed onto a particle surface for use in analyte capture or targeted analyte delivery. In some examples, a Molecular Net is placed on a particle surface (Fig. 9A, 3001) in a circumferential manner whereby a Molecular Net having X, Y and Z spatial orientation may be fairly symmetrical in one layer (3002) and where each layer (examples of 3 layers, 3002, 3003 and 3004) adds to the Z
plane of the particle in differing and asymmetric ways (for example, topology is generated). In some examples, analyte cargo (3003) may be pre-loaded onto capture molecules in one or more layer of a Molecular Net. In outer layers, different capture molecules may be linked into a Molecular Net to generate a topology and/or an affinity for a different target analyte. In some examples, a pre-loaded analyte may comprise a drug, a therapeutic, siRNA, miRNA, dsRNA, virus, toxin, immunogen or other. Pre-loaded cargo may be non-covalently associated with one or more type of capture molecule in a layer of a Molecular Net. In some examples, different capture molecules (3004) of a Molecular Net may be arranged in the outer layers of a Molecular Net and may serve topological and analyte capture roles. The different capture molecules may have specificity for one or more different analyte, the analyte of which may comprise an antibody, an anti-ligand, a ligand, a receptor, an antigen or other and may serve one or more structural and/or affinity and/or targeting role.
plane of the particle in differing and asymmetric ways (for example, topology is generated). In some examples, analyte cargo (3003) may be pre-loaded onto capture molecules in one or more layer of a Molecular Net. In outer layers, different capture molecules may be linked into a Molecular Net to generate a topology and/or an affinity for a different target analyte. In some examples, a pre-loaded analyte may comprise a drug, a therapeutic, siRNA, miRNA, dsRNA, virus, toxin, immunogen or other. Pre-loaded cargo may be non-covalently associated with one or more type of capture molecule in a layer of a Molecular Net. In some examples, different capture molecules (3004) of a Molecular Net may be arranged in the outer layers of a Molecular Net and may serve topological and analyte capture roles. The different capture molecules may have specificity for one or more different analyte, the analyte of which may comprise an antibody, an anti-ligand, a ligand, a receptor, an antigen or other and may serve one or more structural and/or affinity and/or targeting role.
[0087] In some examples, Molecular Nets may be placed onto a particle surface (Fig. 9B, 3005) in a manner whereby analyte cargo (3006) may be pre-loaded in all layers of a Molecular Net. In some layers, capture molecules may be used to generate topological features (3008) that serve particle-targeting roles. In some examples, outer layers of a Molecular Net particle may target said particle to a specific cell, tissue, organ or other.
FIG. 10. Molecular Nets for Analyte Purification from a Sample
FIG. 10. Molecular Nets for Analyte Purification from a Sample
[0088] Molecular Nets may be used in sample purification processes (example is provided in Figure 10). In some examples, Molecular Net designed and fabricated to deplete one or more analyte may be used to treat a sample for analyte depletion. Exemplary methods may include incubation of Molecular Net with sample for about 15 minutes to about 24 hours in a batch slurry or in a chromatography column. Sample supernatant or flowthrough may be collected depending on preferred method. Molecular Nets may be collected and analyzed using various methods for the presence and amount of captured analyte. Molecular Net-treated sample may be collected and analyzed using various methods to determine the residual presence of analyte in the sample or may be analyzed for other analytes in the sample.
FIG. 11. Molecular Nets for Analyte Detection & Measurement from a Sample
FIG. 11. Molecular Nets for Analyte Detection & Measurement from a Sample
[0089] Molecular Nets may be used in an analyte measurement tool or a diagnostic tool (example is provided in Figure 11). In some examples, Molecular Net designed and fabricated to capture one or more analyte may be used to treat a sample for analyte detection and measurement. Exemplary methods may include incubation of Molecular Net with sample for about 15 minutes to about 2 hours in a batch slurry, cassette, slide, microtiter plate or other.
Sample supernatant or flowthrough may be collected depending on preferred method. Molecular Nets may be collected and analyzed using various methods for the presence and amount of captured analyte(s). Molecular Net-treated sample may also be collected and analyzed using various methods to measure other analytes. Methods for measuring changes in Molecular Net characteristics may include optical, electrophoretic, electrical, magnetic, chemical, thermal or other.
Sample supernatant or flowthrough may be collected depending on preferred method. Molecular Nets may be collected and analyzed using various methods for the presence and amount of captured analyte(s). Molecular Net-treated sample may also be collected and analyzed using various methods to measure other analytes. Methods for measuring changes in Molecular Net characteristics may include optical, electrophoretic, electrical, magnetic, chemical, thermal or other.
[0090] While the present invention has been described with reference to the specific embodiments thereof, it should be understood by those skilled in the art that various changes can be made and equivalents can be substituted without departing from the scope of the invention. In addition, many modifications can be made to adapt a particular situation, material, composition of matter, process, process step or steps, to achieve the benefits provided by the present invention without departing from the scope of the present invention. All such modification are intended to be within the scope of the claims appended hereto.
[0091] All publications and patent documents cited herein are incorporated herein by reference as if each such publication or document was specifically and individually indicated to be incorporated herein by reference. Citation of publications and patent documents is not intended as an indication that any such document is pertinent prior art, nor does it constitute any admission as to the contents or date of the same.
Claims (52)
1. A device for capturing an analyte, the device comprising:
a solid phase; and a molecular net coupled to at least a portion of a surface of the solid phase, the molecular net including capture molecules of at least one type coupled to each other by linker molecules of a plurality of types to form a covalently-linked multi-layered three-dimensional matrix, the capture molecules configured to bind to the analyte.
a solid phase; and a molecular net coupled to at least a portion of a surface of the solid phase, the molecular net including capture molecules of at least one type coupled to each other by linker molecules of a plurality of types to form a covalently-linked multi-layered three-dimensional matrix, the capture molecules configured to bind to the analyte.
2. The device of claim 1, wherein the solid phase is made of one or more of a plastic, polymer, thin film, colloidal metal, silica, carbon nanotube, protein, carbohydrate, lipid, nucleic acid, cell, and tissue.
3. The device of claim 1, wherein the solid phase includes one or more of a nanomaterial, modified metal surface, nanosphere, microsphere, microtiter plate, slide, pipette, cassette, cartridge, disc, probe, lateral flow device, microfluidics device, and optical fiber.
4. The device of claim 1, wherein the molecular net is pre-fabricated and absorbed to the surface of the solid phase.
5. The device of claim 1, wherein the molecular net is covalently linked to the surface of the solid phase.
6. The device of claim 1, wherein the molecular net is constructed directly on the surface of the solid phase.
7. The device of claim 1, wherein the capture molecules include one or more of antibodies, nucleic acid probes, enzymes, recombinant proteins, and peptides.
8. The device of claim 1, wherein the capture molecules include a plurality of monoclonal antibodies for binding a plurality of epitopes of the analyte.
9. The device of claim 1, wherein the capture molecules are directed against mutually-confirmatory analytes.
10. The device of claim 1, wherein the linker molecules include one or more of homobifunctional, heterobifunctional, trifunctional, and multifunctional types.
11. The device of claim 1, wherein the molecular net has at least one measurable characteristic that undergoes a change when the capture molecules bind to the analyte.
12. The device of claim 11, wherein the measurable characteristic includes one or more of physical shape, height, density, fluorescence intensity, wavelength shift, vibrational frequency, absorbance, flexibility, refractiveness, conductance, impedance, resistance, melting temperature, denaturation temperature, and freezing temperature.
13. The device of claim 1, wherein the capture molecules are also coupled to each other by a plurality of types of spacer molecules.
14. The device of claim 13, wherein the spacer molecules include one or more of PEGs, polymers, nucleic acids, albumins, Fc regions, and peptides.
15. The device of claim 13, wherein the spacer molecules and an amount of spacer molecules are selected to give the molecular net one or more desired physical properties.
16. The device of claim 15, wherein the desired physical properties include one or more of porosity, charge profile, and topological features.
17. A method of manufacturing a device for capturing an analyte, the method comprising:
providing a solid phase; and placing a molecular net on at least a portion of a surface of the solid phase, the molecular net including capture molecules of at least one type coupled to each other by linker molecules of a plurality of types to form a covalently-linked multi-layered three-dimensional matrix, the capture molecules configured to bind to the analyte.
providing a solid phase; and placing a molecular net on at least a portion of a surface of the solid phase, the molecular net including capture molecules of at least one type coupled to each other by linker molecules of a plurality of types to form a covalently-linked multi-layered three-dimensional matrix, the capture molecules configured to bind to the analyte.
18. The method of claim 17, wherein placing a molecular net on includes pre-fabricating the molecular net and absorbing the molecular net to the surface of the solid phase.
19. The method of claim 17, wherein placing a molecular net on includes covalently linking the molecular net to the surface of the solid phase.
20. The method of claim 17, wherein placing a molecular net on includes constructing the molecular net directly on the surface of the solid phase.
21. A method of measuring a quantity of an analyte in a sample, the method comprising:
providing one or more devices each comprising a solid phase and a molecular net covering at least a portion of a surface of the solid phase, the molecular net including capture molecules of at least one type coupled to each other by linker molecules of a plurality of types to form a covalently-linked multi-layered three-dimensional matrix, the capture molecules configured to bind to the analyte;
exposing the devices to the sample; and allowing at least a portion of the analyte to bind to the capture molecules of the molecular nets of the devices.
providing one or more devices each comprising a solid phase and a molecular net covering at least a portion of a surface of the solid phase, the molecular net including capture molecules of at least one type coupled to each other by linker molecules of a plurality of types to form a covalently-linked multi-layered three-dimensional matrix, the capture molecules configured to bind to the analyte;
exposing the devices to the sample; and allowing at least a portion of the analyte to bind to the capture molecules of the molecular nets of the devices.
22. The method of claim 21, further comprising measuring a change in the sample.
23. The method of claim 22, wherein measuring the change includes using one or more of a photonic multichannel analyzer, spectrometer, magnetic resonance imager, magnetic field detector, optical fiber, glass pipette, circuit, fluorometer, spectroscopic analyzer, potentiostat, calorimeter, electrophoresis, flow cytometer, CCD camera, microscope, acoustic chamber, microphone, and luminometer.
24. The method of claim 21, wherein the molecular net has at least one measurable characteristic that undergoes a change when the capture molecules bind to the analyte.
25. The method of claim 24, further comprising measuring the change in the measurable characteristic of the molecular nets.
26. The method of claim 25, wherein measuring the change includes using one or more of a photonic multichannel analyzer, spectrometer, magnetic resonance imager, magnetic field detector, optical fiber, glass pipette, circuit, fluorometer, spectroscopic analyzer, potentiostat, calorimeter, electrophoresis, flow cytometer, CCD camera, microscope, acoustic chamber, microphone, and luminometer.
27. A device for capturing an analyte, the device comprising:
a solid phase; and a plurality of layers coupled to at least a portion of a surface of the solid phase, the layers comprising a molecular net including capture molecules of at least one type coupled to each other by linker molecules of a plurality of types to form a covalently-linked multi-layered three-dimensional matrix, the capture molecules configured to bind to the analyte.
a solid phase; and a plurality of layers coupled to at least a portion of a surface of the solid phase, the layers comprising a molecular net including capture molecules of at least one type coupled to each other by linker molecules of a plurality of types to form a covalently-linked multi-layered three-dimensional matrix, the capture molecules configured to bind to the analyte.
28. The device of claim 27, wherein the solid phase is made of one or more of a plastic, polymer, thin film, colloidal metal, silica, carbon nanotube, protein, carbohydrate, lipid, nucleic acid, cell, and tissue.
29. The device of claim 27, wherein the solid phase includes one or more of a nanomaterial, modified metal surface, nanosphere, microsphere, microtiter plate, slide, pipette, cassette, cartridge, disc, probe, lateral flow device, microfluidics device, and optical fiber.
30. The device of claim 27, wherein the molecular net is pre-fabricated and absorbed to the surface of the solid phase.
31. The device of claim 27, wherein the molecular net is covalently linked to the surface of the solid phase.
32. The device of claim 27, wherein the molecular net is constructed directly on the surface of the solid phase.
33. The device of claim 27, wherein the capture molecules include one or more of antibodies, nucleic acid probes, enzymes, recombinant proteins, and peptides.
34. The device of claim 27, wherein the capture molecules include a plurality of monoclonal antibodies for binding a plurality of epitopes of the analyte.
35. The device of claim 27, wherein the capture molecules are directed against mutually-confirmatory analytes.
36. The device of claim 27, wherein the linker molecules include one or more of homobifunctional, heterobifunctional, trifunctional, and multifunctional types.
37. The device of claim 27, wherein the molecular net has at least one measurable characteristic that undergoes a change when the capture molecules bind to the analyte.
38. The device of claim 37, wherein the measurable characteristic includes one or more of physical shape, height, density, fluorescence intensity, wavelength shift, vibrational frequency, absorbance, flexibility, refractiveness, conductance, impedance, resistance, melting temperature, denaturation temperature, and freezing temperature.
39. The device of claim 27, wherein the capture molecules are also coupled to each other by a plurality of types of spacer molecules.
40. The device of claim 39, wherein the spacer molecules include one or more of PEGs, polymers, nucleic acids, albumins, Fc regions, and peptides.
41. The device of claim 39, wherein the spacer molecules and an amount of spacer molecules are selected to give the molecular net one or more desired physical properties.
42. The device of claim 41, wherein the desired physical properties include one or more of porosity, charge profile, and topological features.
43. A method of manufacturing a device for capturing an analyte, the method comprising:
providing a solid phase; and placing a plurality of layers on at least a portion of a surface of the solid phase, the layers comprising a molecular net including a plurality of types of capture molecules coupled to each other by a plurality of types of linker molecules to form a covalently-linked multi-layered three-dimensional matrix, the capture molecules configured to bind to the analyte.
providing a solid phase; and placing a plurality of layers on at least a portion of a surface of the solid phase, the layers comprising a molecular net including a plurality of types of capture molecules coupled to each other by a plurality of types of linker molecules to form a covalently-linked multi-layered three-dimensional matrix, the capture molecules configured to bind to the analyte.
44. The method of claim 43, wherein placing a plurality of layers on includes pre-fabricating the layers and absorbing the layers to the surface of the solid phase.
45. The method of claim 43, wherein placing a plurality of layers on includes covalently linking the layers to the surface of the solid phase.
46. The method of claim 43, wherein placing a plurality of layers on includes constructing the layers directly on the surface of the solid phase.
47. A method of measuring a quantity of an analyte in a sample, the method comprising:
providing one or more devices each comprising a solid phase and a plurality of layers covering at least a portion of a surface of the solid phase, the layers comprising a molecular net including capture molecules of at least one type coupled to each other by linked molecules of a plurality of types to form a covalently-linked multi-layered three-dimensional matrix, the capture molecules configured to bind to the analyte;
exposing the devices to the sample; and allowing at least a portion of the analyte to bind to the capture molecules of the molecular nets of the devices.
providing one or more devices each comprising a solid phase and a plurality of layers covering at least a portion of a surface of the solid phase, the layers comprising a molecular net including capture molecules of at least one type coupled to each other by linked molecules of a plurality of types to form a covalently-linked multi-layered three-dimensional matrix, the capture molecules configured to bind to the analyte;
exposing the devices to the sample; and allowing at least a portion of the analyte to bind to the capture molecules of the molecular nets of the devices.
48. The method of claim 47, further comprising measuring a change in the sample.
49. The method of claim 48, wherein measuring the change includes using one or more of a photonic multichannel analyzer, spectrometer, magnetic resonance imager, magnetic field detector, optical fiber, glass pipette, circuit, fluorometer, spectroscopic analyzer, potentiostat, calorimeter, electrophoresis, flow cytometer, CCD camera, microscope, acoustic chamber, microphone, and luminometer.
50. The method of claim 47, wherein the molecular net has at least one measurable characteristic that undergoes a change when the capture molecules bind to the analyte.
51. The method of claim 50, further comprising measuring the change in the measurable characteristic of the molecular nets.
52. The method of claim 51, wherein measuring the change includes using one or more of a photonic multichannel analyzer, spectrometer, magnetic resonance imager, magnetic field detector, optical fiber, glass pipette, circuit, fluorometer, spectroscopic analyzer, potentiostat, calorimeter, electrophoresis, flow cytometer, CCD camera, microscope, acoustic chamber, microphone, and luminometer.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361783189P | 2013-03-14 | 2013-03-14 | |
US61/783,189 | 2013-03-14 | ||
US13/938,055 | 2013-07-09 | ||
US13/938,055 US9910040B2 (en) | 2012-07-09 | 2013-07-09 | Molecular nets comprising capture agents and linking agents |
PCT/US2014/029823 WO2014153262A1 (en) | 2013-03-14 | 2014-03-14 | Molecular nets on solid phases |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2908613A1 true CA2908613A1 (en) | 2014-09-25 |
Family
ID=51581466
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2908613A Abandoned CA2908613A1 (en) | 2013-03-14 | 2014-03-14 | Molecular nets on solid phases |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP2972343A4 (en) |
CN (2) | CN110068677A (en) |
AU (1) | AU2014236090B2 (en) |
CA (1) | CA2908613A1 (en) |
WO (1) | WO2014153262A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105930586B (en) * | 2016-04-21 | 2019-02-01 | 郑州轻工业学院 | XOR gate and complementing circut based on locality DNA hair fastener strand replacement reaction |
CN107338185B (en) * | 2017-08-02 | 2019-07-30 | 昆山汇先医药技术有限公司 | The catching method of biomolecule in a kind of cell or solution |
EP3662059A4 (en) | 2017-08-02 | 2021-03-24 | Hemosmart Medical Technology Ltd. | Method for capturing target cells or molecules in solution |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3116995A1 (en) * | 1981-04-29 | 1982-11-25 | Röhm GmbH, 6100 Darmstadt | LATEX FOR IMMOBILIZING BIOLOGICALLY EFFECTIVE SUBSTANCES |
CZ286845B6 (en) * | 1995-03-27 | 2000-07-12 | Ústav Makromolekulární Chemie Av Čr | Immobilization process of proteins on surface of solid objects |
US9201067B2 (en) * | 2003-03-05 | 2015-12-01 | Posco | Size-controlled macromolecule |
CA2460072C (en) * | 2001-09-17 | 2011-04-05 | Pharmacia Diagnostics Ab | Multi-analyte assay device with multi-spot detection zone |
WO2003048736A2 (en) * | 2001-12-05 | 2003-06-12 | University Of Washington | Microfluidic device and surface decoration process for solid phase affinity binding assays |
US20030149246A1 (en) * | 2002-02-01 | 2003-08-07 | Russell John C. | Macromolecular conjugates and processes for preparing the same |
CN1882701B (en) * | 2003-09-18 | 2015-11-25 | Posco公司 | Size-controlled macromole |
CN1984989B (en) * | 2004-06-09 | 2013-03-13 | 病原体切除与诊断科技公司 | Particles embedded in a porous substrate for removing target analyte from a sample |
WO2007067189A2 (en) * | 2004-12-20 | 2007-06-14 | The Regents Of The University Of Colorado | System and methods for biological assays |
CN100420947C (en) * | 2005-05-30 | 2008-09-24 | 孙东旭 | Method for quantitative determination of specific analyte with single trapping agent and reagent kit therefor |
ATE492813T1 (en) * | 2005-09-27 | 2011-01-15 | George Mason Intellectual Prop | METHOD FOR ISOLATION OF ANALYTES FROM A SAMPLE |
JP2009513654A (en) * | 2005-10-25 | 2009-04-02 | ルイジアナ テク ユニバーシティ リサーチ ファウンデーション | Multilayer coatings, coatings, and microcapsules containing polypeptides |
EP1952152B1 (en) * | 2005-10-27 | 2015-09-23 | BIO-RAD Haifa Ltd. | Binding layer and method for its preparation and uses thereof |
US20130052653A1 (en) * | 2009-11-24 | 2013-02-28 | Argos, Inc. | Devices for detection of analytes |
EP2541250A1 (en) * | 2011-06-30 | 2013-01-02 | Koninklijke Philips Electronics N.V. | Molecular architecture on magnetic particles for affinity assays with low non-specific binding |
WO2014011673A2 (en) * | 2012-07-09 | 2014-01-16 | Sevident, Inc. | Molecular nets |
-
2014
- 2014-03-14 CA CA2908613A patent/CA2908613A1/en not_active Abandoned
- 2014-03-14 AU AU2014236090A patent/AU2014236090B2/en not_active Ceased
- 2014-03-14 WO PCT/US2014/029823 patent/WO2014153262A1/en active Application Filing
- 2014-03-14 CN CN201910037871.3A patent/CN110068677A/en active Pending
- 2014-03-14 CN CN201480025377.0A patent/CN105339791B/en active Active
- 2014-03-14 EP EP14768268.6A patent/EP2972343A4/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
EP2972343A1 (en) | 2016-01-20 |
CN110068677A (en) | 2019-07-30 |
WO2014153262A1 (en) | 2014-09-25 |
CN105339791A (en) | 2016-02-17 |
CN105339791B (en) | 2019-02-15 |
EP2972343A4 (en) | 2016-08-24 |
AU2014236090A1 (en) | 2015-10-08 |
AU2014236090B2 (en) | 2019-09-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Liu et al. | Cytokines: from clinical significance to quantification | |
US20210318298A1 (en) | Capture compositions | |
US11085921B2 (en) | Electronic nose or tongue sensors | |
Liu et al. | On-chip structure-switching aptamer-modified magnetic nanobeads for the continuous monitoring of interferon-gamma ex vivo | |
US20080085508A1 (en) | Non-nucleic acid based biobarcode assay for detection of biological materials | |
JP2017503502A (en) | Artificial cell membrane comprising a supported lipid bilayer bound to a probe with tunable mobility and method for analyzing interactions between molecules using the same | |
Park et al. | Selection of DNA aptamer and its application as an electrical biosensor for Zika virus detection in human serum | |
Goulart et al. | Biomarkers for serum diagnosis of infectious diseases and their potential application in novel sensor platforms | |
JP2010133948A (en) | Biosensor and biomolecule detection method using the same | |
AU2014236090B2 (en) | Molecular nets on solid phases | |
Hwang et al. | Aptamer-conjugated live human immune cell based biosensors for the accurate detection of C-reactive protein | |
Shriver-Lake et al. | Simultaneous assay for ten bacteria and toxins in spiked clinical samples using a microflow cytometer | |
Yu et al. | Quantitative evaluation of biological reaction kinetics in confined nanospaces | |
Li et al. | Edge-enhanced microwell immunoassay for highly sensitive protein detection | |
Horgan et al. | Polymer-and colloid-mediated bioassays, sensors and diagnostics | |
WO2006125050A2 (en) | Biobarcode assays for ultra high sensitive detection | |
Dhawan | Signal amplification systems in immunoassays: implications for clinical diagnostics | |
Okuyama et al. | Flow-Based Immunosensing Using the Pore Channel of a Porous Membrane As a Reaction Space | |
Syed et al. | Aptamers and aptasensors as novel approach for microbial detection and identification: an appraisal | |
Chen et al. | Microfluidic Immunosensing Platform Based on a Rolling Circle Amplification-Assisted DNA Dendrimer Probe for Portable and Sensitive Detection of Allergen-Specific IgE | |
Battersby et al. | Optically encoded particles and their applications in multiplexed biomedical assays | |
Xiong et al. | Ultrasensitive detection of Staphylococcal enterotoxin B in milk based on target-triggered assembly of the flower like nucleic acid nanostructure | |
Zhang et al. | Bead-based mesofluidic system for residue analysis of chloramphenicol | |
JP2010091527A (en) | Assay method using surface plasmon | |
KR102026521B1 (en) | Kit and Method for Detecting Target Materials using Asymmetric Beads |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |
Effective date: 20190311 |
|
EEER | Examination request |
Effective date: 20190311 |
|
EEER | Examination request |
Effective date: 20190311 |
|
EEER | Examination request |
Effective date: 20190311 |
|
EEER | Examination request |
Effective date: 20190311 |
|
EEER | Examination request |
Effective date: 20190311 |
|
FZDE | Discontinued |
Effective date: 20240429 |